<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//ACS//DTD ACS Journal DTD v1.02 20061031//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName ACSJournal-v102.dtd?>
<?SourceDTD.Version 1.02?>
<?ConverterInfo.XSLTName acs2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">ACS Omega</journal-id>
    <journal-id journal-id-type="iso-abbrev">ACS Omega</journal-id>
    <journal-id journal-id-type="publisher-id">ao</journal-id>
    <journal-id journal-id-type="coden">acsodf</journal-id>
    <journal-title-group>
      <journal-title>ACS Omega</journal-title>
    </journal-title-group>
    <issn pub-type="epub">2470-1343</issn>
    <publisher>
      <publisher-name>American Chemical Society</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10702315</article-id>
    <article-id pub-id-type="doi">10.1021/acsomega.3c06119</article-id>
    <article-categories>
      <subj-group>
        <subject>Article</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>MetaTox 2.0: Estimating the
Biological Activity Spectra of Drug-like
Compounds Taking into Account Probable Biotransformations</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" corresp="yes" id="ath1">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8916-9675</contrib-id>
        <name>
          <surname>Rudik</surname>
          <given-names>Anastasia V.</given-names>
        </name>
        <xref rid="cor1" ref-type="other">*</xref>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <contrib contrib-type="author" id="ath2">
        <name>
          <surname>Dmitriev</surname>
          <given-names>Alexander V.</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <contrib contrib-type="author" id="ath3">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1757-8004</contrib-id>
        <name>
          <surname>Lagunin</surname>
          <given-names>Alexey A.</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="ath4">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0339-8478</contrib-id>
        <name>
          <surname>Filimonov</surname>
          <given-names>Dmitry A.</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <contrib contrib-type="author" id="ath5">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7937-2621</contrib-id>
        <name>
          <surname>Poroikov</surname>
          <given-names>Vladimir V.</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <aff id="aff1"><label>†</label>Department
of Bioinformatics, <institution>Institute of Biomedical
Chemistry</institution>, 10 Bldg. 8,
Pogodinskaya Str., Moscow 119121, <country>Russia</country></aff>
      <aff id="aff2"><label>‡</label>Department
of Bioinformatics, <institution>Pirogov Russian National
Research Medical University</institution>, 1 Ostrovityanova Str., Moscow 117997, <country>Russia</country></aff>
    </contrib-group>
    <author-notes>
      <corresp id="cor1"><label>*</label>Email: <email>rudik_anastassia@mail.ru</email>.</corresp>
    </author-notes>
    <pub-date pub-type="epub">
      <day>23</day>
      <month>11</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="collection">
      <day>05</day>
      <month>12</month>
      <year>2023</year>
    </pub-date>
    <volume>8</volume>
    <issue>48</issue>
    <fpage>45774</fpage>
    <lpage>45778</lpage>
    <history>
      <date date-type="received">
        <day>28</day>
        <month>08</month>
        <year>2023</year>
      </date>
      <date date-type="accepted">
        <day>15</day>
        <month>11</month>
        <year>2023</year>
      </date>
      <date date-type="rev-recd">
        <day>12</day>
        <month>11</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2023 The Authors. Published by American Chemical Society</copyright-statement>
      <copyright-year>2023</copyright-year>
      <copyright-holder>The Authors</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
        <license-p>Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>).</license-p>
      </license>
    </permissions>
    <abstract>
      <p content-type="toc-graphic">
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao3c06119_0004" id="ab-tgr1"/>
      </p>
      <p>After the biotransformation
of xenobiotics in the human body, the
biological activity of the metabolites may differ from the activity
of parent compounds. Therefore, to assess the overall biological activity
of a drug-like compound, it is important to take into account its
metabolites and their biological activity. We developed MetaTox 2.0—an
updated version of the MetaTox web application that was able to predict
the metabolites of xenobiotics. Innovations include estimating the
biological activity profile of a compound and taking into account
its metabolites. The estimation is based on the PASS (prediction of
activity spectra for substances) algorithm and on the latest version
of the training set covering over 1900 biological activities predicted
with an average accuracy exceeding 0.97. Also, MetaTox 2.0 allows
the search for similar substances among more than 2000 drugs with
known metabolic networks, which were extracted from the ChEMBL, MetXBIODB,
and DrugBank databases. MetaTox 2.0 is freely available on the web
at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.way2drug.com/metatox">https://www.way2drug.com/metatox</uri>.</p>
    </abstract>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>Russian Science Foundation</institution>
            <institution-id institution-id-type="doi">10.13039/501100006769</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>19-15-00396</award-id>
      </award-group>
    </funding-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>document-id-old-9</meta-name>
        <meta-value>ao3c06119</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>document-id-new-14</meta-name>
        <meta-value>ao3c06119</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>ccc-price</meta-name>
        <meta-value/>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="sec1">
    <label>1</label>
    <title>Introduction</title>
    <p>Biotransformations of
drug-like compounds in the human body could
lead to adverse effects caused by their metabolites.<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> In addition, metabolites may interact with the same target
as the parent compound or may change the clinical outcome by acting
on some other targets.<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> During the drug
development process, it is not always possible to experimentally determine
the structures of all possible metabolites at the early stages of
research.<sup><xref ref-type="bibr" rid="ref3">3</xref></sup> To improve the safety profile
of new drugs, in silico methods may be applied to estimate the biological
activity profile, including toxicity and side effects, based on the
structural formulas of both parent compounds and their potential metabolites.</p>
    <p>There are some freely available web applications that are able
to predict possible biotransformations of xenobiotics. Some examples
include Gloryx,<sup><xref ref-type="bibr" rid="ref4">4</xref></sup> XenoNet,<sup><xref ref-type="bibr" rid="ref5">5</xref></sup> the Metabolic Forest,<sup><xref ref-type="bibr" rid="ref6">6</xref></sup> etc.
However, there is no freely available web application that allows
evaluation of the aggregated biological activity spectrum for the
parent compound based on its putative biotransformation and metabolites.</p>
    <p>Earlier, we developed the web application MetaTox,<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> which was able to generate possible xenobiotics metabolic
pathways in the human organism. The assessment of the generated metabolite
probability formation is based on the biotransformation reactions’
probabilities aggregated with an estimation of a place in the molecule
where the metabolic reaction occurs. The MetaTox algorithm is based
on the Naive Bayes classifier implemented in the PASS (prediction
of activity spectra for substances) software.<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> The generated possible metabolic network was visualized as a tree,
and for each node (compound) on the tree, acute toxicity values (LD<sub>50</sub>) for rats in four types of administrations<sup><xref ref-type="bibr" rid="ref9">9</xref></sup> were predicted.</p>
    <p>Here, we represent a new version
of MetaTox (MetaTox 2.0), in which
we have implemented some essential novel features. The innovations
are presented as gray rectangles in <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>. The first one is the aggregation mechanism
of the biological activity profile prediction for the compound, taking
into account the prediction for all its metabolites. The second one
is searching for compounds similar to the parent compound among the
drugs with known metabolic networks, and the third one is the creation
(drawing) of any metabolic networks with subsequent estimation of
the aggregated profile of biological activity for all network nodes.</p>
    <fig id="fig1" position="float">
      <label>Figure 1</label>
      <caption>
        <p>Scheme
of MetaTox 2.0.</p>
      </caption>
      <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao3c06119_0001" id="gr1" position="float"/>
    </fig>
  </sec>
  <sec id="sec2">
    <label>2</label>
    <title>Materials and Methods</title>
    <sec id="sec2.1">
      <label>2.1</label>
      <title>Metabolic Network Estimation</title>
      <p>The
algorithm, which is implemented in MetaTox 2.0 for the generation
and assessment of metabolites, remained the same as that published
earlier.<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> MetaTox 2.0 generates metabolites
for 19 biotransformation reactions (the first version of MetaTox predicted
nine biotransformation reactions,<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> its
update in the year 2019 included 15 biotransformation reactions<sup><xref ref-type="bibr" rid="ref10">10</xref></sup>). A complete list of MetaTox biotransformation
reactions and their characteristics in the training set are represented
in <xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>. The reactions
that were added compared to the publication of Rudik with coauthors<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> are bolded. The training sets for the models
predicting the previously published biotransformation reactions<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> were also updated. To estimate the accuracy
of the prediction models, we used the invariant accuracy of prediction
(IAP) calculated by the leave-one-out cross-validation (LOO CV) procedure.
The IAP parameter is equivalent to the ROC AUC.<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> The IAP<sub>reaction</sub> is the IAP calculated for the
models, which were used to estimate the probability that a compound
would undergo a given biotransformation reaction. The IAP<sub>SOM</sub> is the IAP calculated for the models, which are used to estimate
the probability that a concerned atom would be a site of metabolism
(SOM) of a given biotransformation reaction, and <italic>N</italic><sub>comp</sub> is the number of compounds in the training set.</p>
      <table-wrap id="tbl1" position="float">
        <label>Table 1</label>
        <caption>
          <title>List of Biotransformation Reactions
Presented in MetaTox 2.0</title>
        </caption>
        <table frame="hsides" rules="groups" border="0">
          <colgroup>
            <col align="left"/>
            <col align="char" char="."/>
            <col align="char" char="."/>
            <col align="char" char="."/>
          </colgroup>
          <thead>
            <tr>
              <th style="border:none;" align="center">biotransformation
reactions</th>
              <th style="border:none;" align="center" char=".">
                <italic>N</italic>
                <sub>comp</sub>
              </th>
              <th style="border:none;" align="center" char=".">IAP<sub>reaction</sub></th>
              <th style="border:none;" align="center" char=".">IAP<sub>SOM</sub></th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td style="border:none;" align="left">aliphatic hydroxylation</td>
              <td style="border:none;" align="char" char=".">407</td>
              <td style="border:none;" align="char" char=".">0.82</td>
              <td style="border:none;" align="char" char=".">0.91</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">aromatic hydroxylation</td>
              <td style="border:none;" align="char" char=".">322</td>
              <td style="border:none;" align="char" char=".">0.84</td>
              <td style="border:none;" align="char" char=".">0.92</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">C-oxidation</td>
              <td style="border:none;" align="char" char=".">145</td>
              <td style="border:none;" align="char" char=".">0.80</td>
              <td style="border:none;" align="char" char=".">0.86</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">dehydrogenation</td>
              <td style="border:none;" align="char" char=".">119</td>
              <td style="border:none;" align="char" char=".">0.81</td>
              <td style="border:none;" align="char" char=".">0.91</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">epoxidation</td>
              <td style="border:none;" align="char" char=".">355</td>
              <td style="border:none;" align="char" char=".">0.89</td>
              <td style="border:none;" align="char" char=".">0.93</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">glutathionylation</td>
              <td style="border:none;" align="char" char=".">477</td>
              <td style="border:none;" align="char" char=".">0.87</td>
              <td style="border:none;" align="char" char=".">0.88</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">
                <bold>hydrogenation</bold>
              </td>
              <td style="border:none;" align="char" char=".">
                <bold>580</bold>
              </td>
              <td style="border:none;" align="char" char=".">
                <bold>0.87</bold>
              </td>
              <td style="border:none;" align="char" char=".">
                <bold>0.87</bold>
              </td>
            </tr>
            <tr>
              <td style="border:none;" align="left">hydrolysis</td>
              <td style="border:none;" align="char" char=".">3220</td>
              <td style="border:none;" align="char" char=".">0.92</td>
              <td style="border:none;" align="char" char=".">0.99</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">
                <bold>methylation</bold>
              </td>
              <td style="border:none;" align="char" char=".">
                <bold>266</bold>
              </td>
              <td style="border:none;" align="char" char=".">
                <bold>0.89</bold>
              </td>
              <td style="border:none;" align="char" char=".">
                <bold>0.96</bold>
              </td>
            </tr>
            <tr>
              <td style="border:none;" align="left">N-acetylation</td>
              <td style="border:none;" align="char" char=".">351</td>
              <td style="border:none;" align="char" char=".">0.95</td>
              <td style="border:none;" align="char" char=".">0.99</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">N-dealkylation</td>
              <td style="border:none;" align="char" char=".">397</td>
              <td style="border:none;" align="char" char=".">0.93</td>
              <td style="border:none;" align="char" char=".">0.97</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">N-glucuronidation</td>
              <td style="border:none;" align="char" char=".">309</td>
              <td style="border:none;" align="char" char=".">0.91</td>
              <td style="border:none;" align="char" char=".">0.99</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">
                <bold>N-hydroxylation</bold>
              </td>
              <td style="border:none;" align="char" char=".">
                <bold>112</bold>
              </td>
              <td style="border:none;" align="char" char=".">
                <bold>0.91</bold>
              </td>
              <td style="border:none;" align="char" char=".">
                <bold>0.99</bold>
              </td>
            </tr>
            <tr>
              <td style="border:none;" align="left">N-oxidation</td>
              <td style="border:none;" align="char" char=".">115</td>
              <td style="border:none;" align="char" char=".">0.90</td>
              <td style="border:none;" align="char" char=".">0.99</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">O-dealkylation</td>
              <td style="border:none;" align="char" char=".">279</td>
              <td style="border:none;" align="char" char=".">0.90</td>
              <td style="border:none;" align="char" char=".">0.99</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">O-glucuronidation</td>
              <td style="border:none;" align="char" char=".">2454</td>
              <td style="border:none;" align="char" char=".">0.87</td>
              <td style="border:none;" align="char" char=".">0.99</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">
                <bold>O-phosphorylation</bold>
              </td>
              <td style="border:none;" align="char" char=".">
                <bold>178</bold>
              </td>
              <td style="border:none;" align="char" char=".">
                <bold>0.99</bold>
              </td>
              <td style="border:none;" align="char" char=".">
                <bold>0.99</bold>
              </td>
            </tr>
            <tr>
              <td style="border:none;" align="left">O-sulfation</td>
              <td style="border:none;" align="char" char=".">764</td>
              <td style="border:none;" align="char" char=".">0.90</td>
              <td style="border:none;" align="char" char=".">0.99</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">S-oxidation</td>
              <td style="border:none;" align="char" char=".">96</td>
              <td style="border:none;" align="char" char=".">0.94</td>
              <td style="border:none;" align="char" char=".">0.99</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
    </sec>
    <sec id="sec2.2">
      <label>2.2</label>
      <title>Biological Activity Spectrum
Estimation</title>
      <p>The PASS software is used for the estimation of
the biological
activity spectrum (BAS) for the parent compounds and their generated
metabolites. MetaTox 2.0 uses the model containing more than 1.5 million
molecules and covering over 1900 types of biological activity predicted
with an average IAP exceeding 0.97, calculated by leave-one-out cross-validation
(LOO CV) (see, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsomega.3c06119/suppl_file/ao3c06119_si_001.pdf">Table S1</ext-link> in the Supporting
Information).</p>
      <p>For any compound from the generated metabolic
networks, three values (Pa, Pi, and Pa_max) are calculated for each
biological activity. Pa (probability “to be active”)
and Pi (probability “to be inactive”) estimate the belonging
of the predicted compound to the classes of active and inactive compounds,
respectively. Pa_max value is the maximum Pa value among all Pa values
calculated for the parent compound and its metabolites. For convenience
of use, the predicted activities are grouped by the category of biological
activity (<xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref>).</p>
      <table-wrap id="tbl2" position="float">
        <label>Table 2</label>
        <caption>
          <title>Category of Biological Activity Used
in MetaTox 2.0<xref rid="t2fn1" ref-type="table-fn">a</xref></title>
        </caption>
        <table frame="hsides" rules="groups" border="0">
          <colgroup>
            <col align="left"/>
            <col align="char" char="."/>
            <col align="char" char="."/>
          </colgroup>
          <thead>
            <tr>
              <th style="border:none;" align="center">category of biological
activity</th>
              <th style="border:none;" align="center" char=".">
                <italic>N</italic>
                <sub>act</sub>
              </th>
              <th style="border:none;" align="center" char=".">IAP<sub>avr</sub></th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td style="border:none;" align="left">antitargets</td>
              <td style="border:none;" align="char" char=".">138</td>
              <td style="border:none;" align="char" char=".">0.98</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">gene expression regulation</td>
              <td style="border:none;" align="char" char=".">14</td>
              <td style="border:none;" align="char" char=".">0.93</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">mechanisms of action</td>
              <td style="border:none;" align="char" char=".">979</td>
              <td style="border:none;" align="char" char=".">0.98</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">metabolism-related actions</td>
              <td style="border:none;" align="char" char=".">45</td>
              <td style="border:none;" align="char" char=".">0.93</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">pharmacological effects</td>
              <td style="border:none;" align="char" char=".">291</td>
              <td style="border:none;" align="char" char=".">0.95</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">toxic and adverse effects</td>
              <td style="border:none;" align="char" char=".">28</td>
              <td style="border:none;" align="char" char=".">0.94</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">transporters-related actions</td>
              <td style="border:none;" align="char" char=".">36</td>
              <td style="border:none;" align="char" char=".">0.99</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="t2fn1">
            <label>a</label>
            <p><italic>N</italic><sub>act</sub> is the total number of predicted
activities, and IAP<sub>avr</sub> is the average IAP calculated in
LOO CV for all activities in the
group.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
    </sec>
    <sec id="sec2.3">
      <label>2.3</label>
      <title>Known
Metabolic Networks’ Similarity</title>
      <p>The DrugBank v 5.1,<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> MetXBIODB,<sup><xref ref-type="bibr" rid="ref13">13</xref></sup> and
ChEMBL v. 33<sup><xref ref-type="bibr" rid="ref14">14</xref></sup> databases were used as sources
of known metabolic pathways. The
total number of pathways that were extracted: 1093 from MetXBIODB,
1013 from DrugBank v.5.1, and 173 from ChEMBL v.33. Metatox 2.0 calculates
the similarity of the original substrate (which was sent to prediction)
with parent compounds from known metabolic networks by two methods.
The first method uses the MNA (multilevel neighborhoods of atoms)
descriptors<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> and Tanimoto coefficient.
The second method uses the QNA (quantitative neighborhood of atoms)
descriptors<sup><xref ref-type="bibr" rid="ref15">15</xref></sup> and a modified Tanimoto coefficient.</p>
    </sec>
    <sec id="sec2.4">
      <label>2.4</label>
      <title>Web Application Development</title>
      <p>The PHP
and Python programming languages were used to develop the server side
of the web application. The vis.js library was used for visualizing
metabolism graphs. HTML, CSS, PHP, and JavaScript were used for the
creation of a web interface (see <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>). The generated graph of metabolism is located
on the left side of the interface. There is a menu on the right side
of the interface, which contains three links to (1) the similarity
table; (2) the aggregated BAS prediction for the selected compound;
(3) detailed information about the compounds; and the button to save
the results in SDF formats.</p>
      <fig id="fig2" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Generated schema of metabolism for irinotecan.
The aggregated profile
of the biological activity of irinotecan is shown on the right side.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao3c06119_0002" id="gr2" position="float"/>
      </fig>
    </sec>
  </sec>
  <sec id="sec3">
    <label>3</label>
    <title>Results and Discussion</title>
    <p>We have created MetaTox 2.0—a new version of the web application
MetaTox, which was initially created for the prediction of xenobiotics’
metabolites. To avoid server load, we have limited the number of metabolites
generated at each level to 10. The new features include aggregated
BAS predictions for pharmaceutical substances and their possible metabolites;
it is also possible to search for compounds with a known metabolic
network that is similar to the compounds submitted for prediction.
An additional feature is the ability to create or draw any metabolic
network and immediately receive the aggregated BAS predictions for
all nodes (compounds) of the network.</p>
    <p>The aggregation of BAS
predictions is performed for all metabolites
of the studied substrate. The prediction result is a table containing
the list of activities and three values (Pa, Pi, and Pa_max) for each
biological activity type. Table rows are highlighted, depending on
the prediction. For example, if the activity is not predicted for
the parent compound (Pa &lt; Pi) but is predicted for its metabolite
(Pa &gt; Pi), the gray color is used for this row. If the activity
is
predicted for the parent compound (Pa &gt; Pi), but the probability
“to
be active” for metabolites is higher (Pa_max &gt; Pa), then
the
brown color is used for this row.</p>
    <p>The next implemented feature
is the calculation of the similarity
to approved drugs and drugs with known metabolic networks. The data
set of known metabolic networks contains more than 2000 graphs of
metabolism from DrugBank, MetXBIODB, and ChEMBL. The structural formula
of the substrate, which is used as a query, is compared with the structures
of parent compounds from the known metabolic networks. The final tables
contain structures and similarity indexes calculated by two methods.
Depending on the selected data set, clicking on a structure will display
the complete known metabolic pathway on the left side of the interface.</p>
    <sec id="sec3.1">
      <label>3.1</label>
      <title>Example of the Web Application Utilization</title>
      <p>The schema
of the generated metabolic network of irinotecan by
MetaTox 2.0 is shown as an example in <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref> (all parameters for generation are selected
by default).</p>
      <p>The user can see the aggregated profile of the
biological activity of irinotecan, which is represented in the form
of a table and grouped into seven categories (activity category).
It is also possible to see how a specific biological activity is predicted.
To obtain this information, the user can start typing the name of
the activity into the field in the upper right corner and then select
the desired activity from the list, which includes only activities
containing a search substring. Users can set up a threshold in the
adjacent field and then click the search button. In <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>, green rectangles with Pa
values appear next to the compounds that have topoisomerase I activity
with Pa &gt;0.8.</p>
      <p>It is known that irinotecan undergoes hydrolysis
with the formation
of the active metabolite SN-38,<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> which
is over 1000 times more potent inhibitor of topoisomerase 1.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> As one can see in <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>, the metabolite SN-38 (metabolite no. 6)
has a higher probability to be a topoisomerase I inhibitor than irinotecan.
A higher probability of biological activity for the metabolite serves
as a signal for a more detailed study of this activity in the parent
compound, since in the case of high concentrations of the metabolite,
this biological activity may play a significant role in the drug effect.</p>
      <p>In addition to generating potential metabolites, users can draw
their own scheme. To do this, the user should go to the section “Make
a new schema” and then select the “Generate New”
option (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>).
To add nodes to the metabolic network, one should enter SMILES and
the names (labels) of substances. If SMILES is correct, the figure
with the substance structure appears after entering “save”.
After clicking on this figure, the user can see the BAS prediction.
Without adding edges, the user receives the BAS prediction only for
the compound itself (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>A). After adding edges, the user receives the BAS prediction,
taking into account all of the metabolites (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>B). For working with the drawn-up schema
in the future, one should remember the task ID and input it into the
corresponding field in the section “Make a new schema”
(<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>).</p>
      <fig id="fig3" position="float">
        <label>Figure 3</label>
        <caption>
          <p>Process of
drawing up a new metabolic schema.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao3c06119_0003" id="gr3" position="float"/>
      </fig>
    </sec>
  </sec>
  <sec id="sec4">
    <label>4</label>
    <title>Conclusions</title>
    <p>The developed MetaTox 2.0 web
application allows the user to generate
probable metabolites or draw up any metabolic network. For any substance
in the network, the user receives a high-precision estimation of the
biological activity profile of a compound, taking into account its
metabolites.</p>
    <p>MetaTox 2.0 provides a valuable resource for researchers
to predict
the metabolic fate of xenobiotics and investigate their potential
efficacy and toxicity effects based on their metabolism, which in
turn could help to identify the most promising compounds for experimental
studies.</p>
  </sec>
</body>
<back>
  <notes id="notes1" notes-type="si">
    <title>Supporting Information Available</title>
    <p>The Supporting Information
is
available free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acsomega.3c06119?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsomega.3c06119</ext-link>.<list id="silist" list-type="simple"><list-item><p>1,957 types of biological
activity predicted by PASS
software (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsomega.3c06119/suppl_file/ao3c06119_si_001.pdf">PDF</ext-link>)</p></list-item></list></p>
  </notes>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material content-type="local-data" id="sifile1">
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao3c06119_si_001.pdf">
        <caption>
          <p>ao3c06119_si_001.pdf</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
  <notes notes-type="" id="notes3">
    <title>Author Contributions</title>
    <p>V.P. initiated
the project. A.D. and A.R. created models for metabolism prediction.
A.R. implemented the code of the web application. D.F. and A.L. created
models for biological activity prediction. A.R. wrote the paper with
constant supervision and feedback from the coauthors. All authors
read, edited, and approved the final manuscript.</p>
  </notes>
  <notes notes-type="COI-statement" id="notes2">
    <p>The
authors
declare no competing financial interest.</p>
  </notes>
  <notes notes-type="" id="notes4">
    <title>Notes</title>
    <p>The MetaTox
2.0 web application is freely available
for query at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.way2drug.com/metatox">https://www.way2drug.com/metatox</uri>.</p>
  </notes>
  <ack>
    <title>Acknowledgments</title>
    <p>The study was carried
out within the framework of
the Russian Science Foundation, project no. 19-15-00396, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://rscf.ru/project/19-15-00396/">https://rscf.ru/project/19-15-00396/</uri>.</p>
  </ack>
  <ref-list>
    <title>References</title>
    <ref id="ref1">
      <mixed-citation publication-type="journal" id="cit1"><name><surname>Baillie</surname><given-names>T. A.</given-names></name>; <name><surname>Rettie</surname><given-names>A. E.</given-names></name><article-title>Role of Biotransformation in Drug-Induced Toxicity :
Influence of Intra- and Inter-Species Differences in Drug Metabolism</article-title>. <source>Drug Metab. Pharmacokinet.</source><year>2011</year>, <volume>26</volume> (<issue>1</issue>), <fpage>15</fpage>–<lpage>29</lpage>. <pub-id pub-id-type="doi">10.2133/dmpk.DMPK-10-RV-089</pub-id>.<pub-id pub-id-type="pmid">20978360</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref2">
      <mixed-citation publication-type="journal" id="cit2"><name><surname>Obach</surname><given-names>R. S.</given-names></name><article-title>Pharmacologically
active drug metabolites: impact on drug discovery and pharmacotherapy</article-title>. <source>Pharmacol. Rev.</source><year>2013</year>, <volume>65</volume> (<issue>2</issue>), <fpage>578</fpage>–<lpage>640</lpage>. <pub-id pub-id-type="doi">10.1124/pr.111.005439</pub-id>.<pub-id pub-id-type="pmid">23406671</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref3">
      <mixed-citation publication-type="journal" id="cit3"><name><surname>Sindelar</surname><given-names>M.</given-names></name>; <name><surname>Patti</surname><given-names>G. J.</given-names></name><article-title>Chemical Discovery in the Era of Metabolomics</article-title>. <source>J. Am. Chem. Soc.</source><year>2020</year>, <volume>142</volume> (<issue>20</issue>), <fpage>9097</fpage>–<lpage>9105</lpage>. <pub-id pub-id-type="doi">10.1021/jacs.9b13198</pub-id>.<pub-id pub-id-type="pmid">32275430</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref4">
      <mixed-citation publication-type="journal" id="cit4"><name><surname>de
Bruyn Kops</surname><given-names>C.</given-names></name>; <name><surname>Šícho</surname><given-names>M.</given-names></name>; <name><surname>Mazzolari</surname><given-names>A.</given-names></name>; <name><surname>Kirchmair</surname><given-names>J.</given-names></name><article-title>GLORYx: Prediction of the Metabolites Resulting from
Phase 1 and Phase 2 Biotransformations of Xenobiotics</article-title>. <source>Chem. Res. Toxicol.</source><year>2021</year>, <volume>34</volume> (<issue>2</issue>), <fpage>286</fpage>–<lpage>299</lpage>. <pub-id pub-id-type="doi">10.1021/acs.chemrestox.0c00224</pub-id>.<pub-id pub-id-type="pmid">32786543</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref5">
      <mixed-citation publication-type="journal" id="cit5"><name><surname>Flynn</surname><given-names>N. R.</given-names></name>; <name><surname>Dang</surname><given-names>N. L.</given-names></name>; <name><surname>Ward</surname><given-names>M. D.</given-names></name>; <name><surname>Swamidass</surname><given-names>S. J.</given-names></name><article-title>XenoNet:
Inference and Likelihood of Intermediate Metabolite Formation</article-title>. <source>J. Chem. Inf. Model.</source><year>2020</year>, <volume>60</volume> (<issue>7</issue>), <fpage>3431</fpage>–<lpage>3449</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.0c00361</pub-id>.<pub-id pub-id-type="pmid">32525671</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref6">
      <mixed-citation publication-type="journal" id="cit6"><name><surname>Hughes</surname><given-names>T. B.</given-names></name>; <name><surname>Dang</surname><given-names>N. L.</given-names></name>; <name><surname>Kumar</surname><given-names>A.</given-names></name>; <name><surname>Flynn</surname><given-names>N. R.</given-names></name>; <name><surname>Swamidass</surname><given-names>S. J.</given-names></name><article-title>Metabolic
Forest: Predicting the Diverse Structures of Drug Metabolites</article-title>. <source>J. Chem. Inf. Model.</source><year>2020</year>, <volume>60</volume> (<issue>10</issue>), <fpage>4702</fpage>–<lpage>4716</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.0c00360</pub-id>.<pub-id pub-id-type="pmid">32881497</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref7">
      <mixed-citation publication-type="journal" id="cit7"><name><surname>Rudik</surname><given-names>A. V.</given-names></name>; <name><surname>Bezhentsev</surname><given-names>V. M.</given-names></name>; <name><surname>Dmitriev</surname><given-names>A. V.</given-names></name>; <name><surname>Druzhilovskiy</surname><given-names>D. S.</given-names></name>; <name><surname>Lagunin</surname><given-names>A. A.</given-names></name>; <name><surname>Filimonov</surname><given-names>D. A.</given-names></name>; <name><surname>Poroikov</surname><given-names>V. V.</given-names></name><article-title>MetaTox: Web Application
for Predicting Structure and Toxicity of Xenobiotics’ Metabolites</article-title>. <source>J. Chem. Inf. Model.</source><year>2017</year>, <volume>57</volume> (<issue>4</issue>), <fpage>638</fpage>–<lpage>642</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.6b00662</pub-id>.<pub-id pub-id-type="pmid">28345905</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref8">
      <mixed-citation publication-type="journal" id="cit8"><name><surname>Filimonov</surname><given-names>D.</given-names></name>; <name><surname>Druzhilovskiy</surname><given-names>D.</given-names></name>; <name><surname>Lagunin</surname><given-names>A.</given-names></name>; <name><surname>Gloriozova</surname><given-names>T.</given-names></name>; <name><surname>Rudik</surname><given-names>A.</given-names></name>; <name><surname>Dmitriev</surname><given-names>A.</given-names></name>; <name><surname>Pogodin</surname><given-names>P.</given-names></name>; <name><surname>Poroikov</surname><given-names>V.</given-names></name><article-title>Computer-aided
prediction of biological activity spectra for chemical compounds:
opportunities and limitation</article-title>. <source>Biomed. Chem.</source><year>2018</year>, <volume>1</volume> (<issue>1</issue>), <elocation-id>e00004</elocation-id><pub-id pub-id-type="doi">10.18097/BMCRM00004</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref9">
      <mixed-citation publication-type="journal" id="cit9"><name><surname>Lagunin</surname><given-names>A.</given-names></name>; <name><surname>Zakharov</surname><given-names>A.</given-names></name>; <name><surname>Filimonov</surname><given-names>D.</given-names></name>; <name><surname>Poroikov</surname><given-names>V.</given-names></name><article-title>QSAR Modelling of Rat
Acute Toxicity on the Basis of PASS Prediction</article-title>. <source>Mol. Inf.</source><year>2011</year>, <volume>30</volume> (<issue>2–3</issue>), <fpage>241</fpage>–<lpage>250</lpage>. <pub-id pub-id-type="doi">10.1002/minf.201000151</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref10">
      <mixed-citation publication-type="journal" id="cit10"><name><surname>Rudik</surname><given-names>A.</given-names></name>; <name><surname>Bezhentsev</surname><given-names>V.</given-names></name>; <name><surname>Dmitriev</surname><given-names>A.</given-names></name>; <name><surname>Lagunin</surname><given-names>A.</given-names></name>; <name><surname>Filimonov</surname><given-names>D.</given-names></name>; <name><surname>Poroikov</surname><given-names>V.</given-names></name><article-title>Metatox - Web application for generation of metabolic
pathways and toxicity estimation</article-title>. <source>J. Bioinf.
Comput. Biol.</source><year>2019</year>, <volume>17</volume> (<issue>01</issue>), <fpage>1940001</fpage><pub-id pub-id-type="doi">10.1142/S0219720019400018</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref11">
      <mixed-citation publication-type="journal" id="cit11"><name><surname>Filimonov</surname><given-names>D. A.</given-names></name>; <name><surname>Druzhilovskiy</surname><given-names>D. S.</given-names></name>; <name><surname>Lagunin</surname><given-names>A. A.</given-names></name>; <name><surname>Gloriozova</surname><given-names>T. A.</given-names></name>; <name><surname>Rudik</surname><given-names>A. V.</given-names></name>; <name><surname>Dmitriev</surname><given-names>A. V.</given-names></name>; <name><surname>Pogodin</surname><given-names>P.</given-names></name>; <name><surname>Poroikov</surname><given-names>V.</given-names></name><article-title>Computer-aided
prediction of biological activity spectra for chemical compounds:
opportunities and limitation</article-title>. <source>Biomed. Chem.</source><year>2018</year>, <volume>1</volume>, <elocation-id>e00004</elocation-id><pub-id pub-id-type="doi">10.18097/BMCRM00004</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref12">
      <mixed-citation publication-type="journal" id="cit12"><name><surname>Wishart</surname><given-names>D. S.</given-names></name>; <name><surname>Feunang</surname><given-names>Y. D.</given-names></name>; <name><surname>Guo</surname><given-names>A. C.</given-names></name>; <name><surname>Lo</surname><given-names>E. J.</given-names></name>; <name><surname>Marcu</surname><given-names>A.</given-names></name>; <name><surname>Grant</surname><given-names>J. R.</given-names></name>; <name><surname>Sajed</surname><given-names>T.</given-names></name>; <name><surname>Johnson</surname><given-names>D.</given-names></name>; <name><surname>Li</surname><given-names>C.</given-names></name>; <name><surname>Sayeeda</surname><given-names>Z.</given-names></name>; <name><surname>Assempour</surname><given-names>N.</given-names></name>; <name><surname>Iynkkaran</surname><given-names>I.</given-names></name>; <name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>Maciejewski</surname><given-names>A.</given-names></name>; <name><surname>Gale</surname><given-names>N.</given-names></name>; <name><surname>Wilson</surname><given-names>A.</given-names></name>; <name><surname>Chin</surname><given-names>L.</given-names></name>; <name><surname>Cummings</surname><given-names>R.</given-names></name>; <name><surname>Le</surname><given-names>D.</given-names></name>; <name><surname>Pon</surname><given-names>A.</given-names></name>; <name><surname>Knox</surname><given-names>C.</given-names></name>; et al. <article-title>DrugBank 5.0: a major update to the DrugBank database for 2018</article-title>. <source>Nucleic Acids Res.</source><year>2018</year>, <volume>46</volume> (<issue>D1</issue>), <fpage>D1074</fpage>–<lpage>D1082</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkx1037</pub-id>.<pub-id pub-id-type="pmid">29126136</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref13">
      <mixed-citation publication-type="journal" id="cit13"><name><surname>Djoumbou-Feunang</surname><given-names>Y.</given-names></name>; <name><surname>Fiamoncini</surname><given-names>J.</given-names></name>; <name><surname>Gil-de-la-Fuente</surname><given-names>A.</given-names></name>; <name><surname>Greiner</surname><given-names>R.</given-names></name>; <name><surname>Manach</surname><given-names>C.</given-names></name>; <name><surname>Wishart</surname><given-names>D. S.</given-names></name><article-title>BioTransformer: a comprehensive computational tool
for small molecule metabolism prediction and metabolite identification</article-title>. <source>J. Cheminf.</source><year>2019</year>, <volume>11</volume> (<issue>1</issue>), <fpage>2</fpage><pub-id pub-id-type="doi">10.1186/s13321-018-0324-5</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref14">
      <mixed-citation publication-type="journal" id="cit14"><name><surname>Mendez</surname><given-names>D.</given-names></name>; <name><surname>Gaulton</surname><given-names>A.</given-names></name>; <name><surname>Bento</surname><given-names>A. P.</given-names></name>; <name><surname>Chambers</surname><given-names>J.</given-names></name>; <name><surname>De Veij</surname><given-names>M.</given-names></name>; <name><surname>Félix</surname><given-names>E.</given-names></name>; <name><surname>Magariños</surname><given-names>M.</given-names></name>; <name><surname>Mosquera</surname><given-names>J. F.</given-names></name>; <name><surname>Mutowo</surname><given-names>P.</given-names></name>; <name><surname>Nowotka</surname><given-names>M.</given-names></name>; <name><surname>Gordillo-Marañón</surname><given-names>M.</given-names></name>; <name><surname>Hunter</surname><given-names>F.</given-names></name>; <name><surname>Junco</surname><given-names>L.</given-names></name>; <name><surname>Mugumbate</surname><given-names>G.</given-names></name>; <name><surname>Rodriguez-Lopez</surname><given-names>M.</given-names></name>; <name><surname>Atkinson</surname><given-names>F.</given-names></name>; <name><surname>Bosc</surname><given-names>N.</given-names></name>; <name><surname>Radoux</surname><given-names>C. J.</given-names></name>; <name><surname>Segura-Cabrera</surname><given-names>A.</given-names></name>; <name><surname>Hersey</surname><given-names>A.</given-names></name>; <name><surname>Leach</surname><given-names>A. R.</given-names></name><article-title>ChEMBL:
towards
direct deposition of bioassay data</article-title>. <source>Nucleic
Acids Res.</source><year>2019</year>, <volume>47</volume> (<issue>D1</issue>), <fpage>D930</fpage>–<lpage>D940</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gky1075</pub-id>.<pub-id pub-id-type="pmid">30398643</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref15">
      <mixed-citation publication-type="journal" id="cit15"><name><surname>Filimonov</surname><given-names>D.</given-names></name>; <name><surname>Zakharov</surname><given-names>A.</given-names></name>; <name><surname>Lagunin</surname><given-names>A.</given-names></name>; <name><surname>Poroikov</surname><given-names>V.</given-names></name><article-title>QNA-based “Star
Track” QSAR approach</article-title>. <source>SAR QSAR Environ.
Res.</source><year>2009</year>, <volume>20</volume> (<issue>7–8</issue>), <fpage>679</fpage>–<lpage>709</lpage>. <pub-id pub-id-type="doi">10.1080/10629360903438370</pub-id>.<pub-id pub-id-type="pmid">20024804</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref16">
      <mixed-citation publication-type="journal" id="cit16"><name><surname>Kawato</surname><given-names>Y.</given-names></name>; <name><surname>Aonuma</surname><given-names>M.</given-names></name>; <name><surname>Hirota</surname><given-names>Y.</given-names></name>; <name><surname>Kuga</surname><given-names>H.</given-names></name>; <name><surname>Sato</surname><given-names>K.</given-names></name><article-title>Intracellular
roles of SN-38, a metabolite of the camptothecin derivative CPT-11,
in the antitumor effect of CPT-11</article-title>. <source>Cancer Res.</source><year>1991</year>, <volume>51</volume> (<issue>16</issue>), <fpage>4187</fpage>–<lpage>4191</lpage>.<pub-id pub-id-type="pmid">1651156</pub-id>
</mixed-citation>
    </ref>
  </ref-list>
</back>
<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//ACS//DTD ACS Journal DTD v1.02 20061031//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName ACSJournal-v102.dtd?>
<?SourceDTD.Version 1.02?>
<?ConverterInfo.XSLTName acs2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">ACS Omega</journal-id>
    <journal-id journal-id-type="iso-abbrev">ACS Omega</journal-id>
    <journal-id journal-id-type="publisher-id">ao</journal-id>
    <journal-id journal-id-type="coden">acsodf</journal-id>
    <journal-title-group>
      <journal-title>ACS Omega</journal-title>
    </journal-title-group>
    <issn pub-type="epub">2470-1343</issn>
    <publisher>
      <publisher-name>American Chemical Society</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10702315</article-id>
    <article-id pub-id-type="doi">10.1021/acsomega.3c06119</article-id>
    <article-categories>
      <subj-group>
        <subject>Article</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>MetaTox 2.0: Estimating the
Biological Activity Spectra of Drug-like
Compounds Taking into Account Probable Biotransformations</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" corresp="yes" id="ath1">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8916-9675</contrib-id>
        <name>
          <surname>Rudik</surname>
          <given-names>Anastasia V.</given-names>
        </name>
        <xref rid="cor1" ref-type="other">*</xref>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <contrib contrib-type="author" id="ath2">
        <name>
          <surname>Dmitriev</surname>
          <given-names>Alexander V.</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <contrib contrib-type="author" id="ath3">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1757-8004</contrib-id>
        <name>
          <surname>Lagunin</surname>
          <given-names>Alexey A.</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="ath4">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0339-8478</contrib-id>
        <name>
          <surname>Filimonov</surname>
          <given-names>Dmitry A.</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <contrib contrib-type="author" id="ath5">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7937-2621</contrib-id>
        <name>
          <surname>Poroikov</surname>
          <given-names>Vladimir V.</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <aff id="aff1"><label>†</label>Department
of Bioinformatics, <institution>Institute of Biomedical
Chemistry</institution>, 10 Bldg. 8,
Pogodinskaya Str., Moscow 119121, <country>Russia</country></aff>
      <aff id="aff2"><label>‡</label>Department
of Bioinformatics, <institution>Pirogov Russian National
Research Medical University</institution>, 1 Ostrovityanova Str., Moscow 117997, <country>Russia</country></aff>
    </contrib-group>
    <author-notes>
      <corresp id="cor1"><label>*</label>Email: <email>rudik_anastassia@mail.ru</email>.</corresp>
    </author-notes>
    <pub-date pub-type="epub">
      <day>23</day>
      <month>11</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="collection">
      <day>05</day>
      <month>12</month>
      <year>2023</year>
    </pub-date>
    <volume>8</volume>
    <issue>48</issue>
    <fpage>45774</fpage>
    <lpage>45778</lpage>
    <history>
      <date date-type="received">
        <day>28</day>
        <month>08</month>
        <year>2023</year>
      </date>
      <date date-type="accepted">
        <day>15</day>
        <month>11</month>
        <year>2023</year>
      </date>
      <date date-type="rev-recd">
        <day>12</day>
        <month>11</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2023 The Authors. Published by American Chemical Society</copyright-statement>
      <copyright-year>2023</copyright-year>
      <copyright-holder>The Authors</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
        <license-p>Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>).</license-p>
      </license>
    </permissions>
    <abstract>
      <p content-type="toc-graphic">
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao3c06119_0004" id="ab-tgr1"/>
      </p>
      <p>After the biotransformation
of xenobiotics in the human body, the
biological activity of the metabolites may differ from the activity
of parent compounds. Therefore, to assess the overall biological activity
of a drug-like compound, it is important to take into account its
metabolites and their biological activity. We developed MetaTox 2.0—an
updated version of the MetaTox web application that was able to predict
the metabolites of xenobiotics. Innovations include estimating the
biological activity profile of a compound and taking into account
its metabolites. The estimation is based on the PASS (prediction of
activity spectra for substances) algorithm and on the latest version
of the training set covering over 1900 biological activities predicted
with an average accuracy exceeding 0.97. Also, MetaTox 2.0 allows
the search for similar substances among more than 2000 drugs with
known metabolic networks, which were extracted from the ChEMBL, MetXBIODB,
and DrugBank databases. MetaTox 2.0 is freely available on the web
at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.way2drug.com/metatox">https://www.way2drug.com/metatox</uri>.</p>
    </abstract>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>Russian Science Foundation</institution>
            <institution-id institution-id-type="doi">10.13039/501100006769</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>19-15-00396</award-id>
      </award-group>
    </funding-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>document-id-old-9</meta-name>
        <meta-value>ao3c06119</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>document-id-new-14</meta-name>
        <meta-value>ao3c06119</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>ccc-price</meta-name>
        <meta-value/>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="sec1">
    <label>1</label>
    <title>Introduction</title>
    <p>Biotransformations of
drug-like compounds in the human body could
lead to adverse effects caused by their metabolites.<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> In addition, metabolites may interact with the same target
as the parent compound or may change the clinical outcome by acting
on some other targets.<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> During the drug
development process, it is not always possible to experimentally determine
the structures of all possible metabolites at the early stages of
research.<sup><xref ref-type="bibr" rid="ref3">3</xref></sup> To improve the safety profile
of new drugs, in silico methods may be applied to estimate the biological
activity profile, including toxicity and side effects, based on the
structural formulas of both parent compounds and their potential metabolites.</p>
    <p>There are some freely available web applications that are able
to predict possible biotransformations of xenobiotics. Some examples
include Gloryx,<sup><xref ref-type="bibr" rid="ref4">4</xref></sup> XenoNet,<sup><xref ref-type="bibr" rid="ref5">5</xref></sup> the Metabolic Forest,<sup><xref ref-type="bibr" rid="ref6">6</xref></sup> etc.
However, there is no freely available web application that allows
evaluation of the aggregated biological activity spectrum for the
parent compound based on its putative biotransformation and metabolites.</p>
    <p>Earlier, we developed the web application MetaTox,<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> which was able to generate possible xenobiotics metabolic
pathways in the human organism. The assessment of the generated metabolite
probability formation is based on the biotransformation reactions’
probabilities aggregated with an estimation of a place in the molecule
where the metabolic reaction occurs. The MetaTox algorithm is based
on the Naive Bayes classifier implemented in the PASS (prediction
of activity spectra for substances) software.<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> The generated possible metabolic network was visualized as a tree,
and for each node (compound) on the tree, acute toxicity values (LD<sub>50</sub>) for rats in four types of administrations<sup><xref ref-type="bibr" rid="ref9">9</xref></sup> were predicted.</p>
    <p>Here, we represent a new version
of MetaTox (MetaTox 2.0), in which
we have implemented some essential novel features. The innovations
are presented as gray rectangles in <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>. The first one is the aggregation mechanism
of the biological activity profile prediction for the compound, taking
into account the prediction for all its metabolites. The second one
is searching for compounds similar to the parent compound among the
drugs with known metabolic networks, and the third one is the creation
(drawing) of any metabolic networks with subsequent estimation of
the aggregated profile of biological activity for all network nodes.</p>
    <fig id="fig1" position="float">
      <label>Figure 1</label>
      <caption>
        <p>Scheme
of MetaTox 2.0.</p>
      </caption>
      <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao3c06119_0001" id="gr1" position="float"/>
    </fig>
  </sec>
  <sec id="sec2">
    <label>2</label>
    <title>Materials and Methods</title>
    <sec id="sec2.1">
      <label>2.1</label>
      <title>Metabolic Network Estimation</title>
      <p>The
algorithm, which is implemented in MetaTox 2.0 for the generation
and assessment of metabolites, remained the same as that published
earlier.<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> MetaTox 2.0 generates metabolites
for 19 biotransformation reactions (the first version of MetaTox predicted
nine biotransformation reactions,<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> its
update in the year 2019 included 15 biotransformation reactions<sup><xref ref-type="bibr" rid="ref10">10</xref></sup>). A complete list of MetaTox biotransformation
reactions and their characteristics in the training set are represented
in <xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>. The reactions
that were added compared to the publication of Rudik with coauthors<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> are bolded. The training sets for the models
predicting the previously published biotransformation reactions<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> were also updated. To estimate the accuracy
of the prediction models, we used the invariant accuracy of prediction
(IAP) calculated by the leave-one-out cross-validation (LOO CV) procedure.
The IAP parameter is equivalent to the ROC AUC.<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> The IAP<sub>reaction</sub> is the IAP calculated for the
models, which were used to estimate the probability that a compound
would undergo a given biotransformation reaction. The IAP<sub>SOM</sub> is the IAP calculated for the models, which are used to estimate
the probability that a concerned atom would be a site of metabolism
(SOM) of a given biotransformation reaction, and <italic>N</italic><sub>comp</sub> is the number of compounds in the training set.</p>
      <table-wrap id="tbl1" position="float">
        <label>Table 1</label>
        <caption>
          <title>List of Biotransformation Reactions
Presented in MetaTox 2.0</title>
        </caption>
        <table frame="hsides" rules="groups" border="0">
          <colgroup>
            <col align="left"/>
            <col align="char" char="."/>
            <col align="char" char="."/>
            <col align="char" char="."/>
          </colgroup>
          <thead>
            <tr>
              <th style="border:none;" align="center">biotransformation
reactions</th>
              <th style="border:none;" align="center" char=".">
                <italic>N</italic>
                <sub>comp</sub>
              </th>
              <th style="border:none;" align="center" char=".">IAP<sub>reaction</sub></th>
              <th style="border:none;" align="center" char=".">IAP<sub>SOM</sub></th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td style="border:none;" align="left">aliphatic hydroxylation</td>
              <td style="border:none;" align="char" char=".">407</td>
              <td style="border:none;" align="char" char=".">0.82</td>
              <td style="border:none;" align="char" char=".">0.91</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">aromatic hydroxylation</td>
              <td style="border:none;" align="char" char=".">322</td>
              <td style="border:none;" align="char" char=".">0.84</td>
              <td style="border:none;" align="char" char=".">0.92</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">C-oxidation</td>
              <td style="border:none;" align="char" char=".">145</td>
              <td style="border:none;" align="char" char=".">0.80</td>
              <td style="border:none;" align="char" char=".">0.86</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">dehydrogenation</td>
              <td style="border:none;" align="char" char=".">119</td>
              <td style="border:none;" align="char" char=".">0.81</td>
              <td style="border:none;" align="char" char=".">0.91</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">epoxidation</td>
              <td style="border:none;" align="char" char=".">355</td>
              <td style="border:none;" align="char" char=".">0.89</td>
              <td style="border:none;" align="char" char=".">0.93</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">glutathionylation</td>
              <td style="border:none;" align="char" char=".">477</td>
              <td style="border:none;" align="char" char=".">0.87</td>
              <td style="border:none;" align="char" char=".">0.88</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">
                <bold>hydrogenation</bold>
              </td>
              <td style="border:none;" align="char" char=".">
                <bold>580</bold>
              </td>
              <td style="border:none;" align="char" char=".">
                <bold>0.87</bold>
              </td>
              <td style="border:none;" align="char" char=".">
                <bold>0.87</bold>
              </td>
            </tr>
            <tr>
              <td style="border:none;" align="left">hydrolysis</td>
              <td style="border:none;" align="char" char=".">3220</td>
              <td style="border:none;" align="char" char=".">0.92</td>
              <td style="border:none;" align="char" char=".">0.99</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">
                <bold>methylation</bold>
              </td>
              <td style="border:none;" align="char" char=".">
                <bold>266</bold>
              </td>
              <td style="border:none;" align="char" char=".">
                <bold>0.89</bold>
              </td>
              <td style="border:none;" align="char" char=".">
                <bold>0.96</bold>
              </td>
            </tr>
            <tr>
              <td style="border:none;" align="left">N-acetylation</td>
              <td style="border:none;" align="char" char=".">351</td>
              <td style="border:none;" align="char" char=".">0.95</td>
              <td style="border:none;" align="char" char=".">0.99</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">N-dealkylation</td>
              <td style="border:none;" align="char" char=".">397</td>
              <td style="border:none;" align="char" char=".">0.93</td>
              <td style="border:none;" align="char" char=".">0.97</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">N-glucuronidation</td>
              <td style="border:none;" align="char" char=".">309</td>
              <td style="border:none;" align="char" char=".">0.91</td>
              <td style="border:none;" align="char" char=".">0.99</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">
                <bold>N-hydroxylation</bold>
              </td>
              <td style="border:none;" align="char" char=".">
                <bold>112</bold>
              </td>
              <td style="border:none;" align="char" char=".">
                <bold>0.91</bold>
              </td>
              <td style="border:none;" align="char" char=".">
                <bold>0.99</bold>
              </td>
            </tr>
            <tr>
              <td style="border:none;" align="left">N-oxidation</td>
              <td style="border:none;" align="char" char=".">115</td>
              <td style="border:none;" align="char" char=".">0.90</td>
              <td style="border:none;" align="char" char=".">0.99</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">O-dealkylation</td>
              <td style="border:none;" align="char" char=".">279</td>
              <td style="border:none;" align="char" char=".">0.90</td>
              <td style="border:none;" align="char" char=".">0.99</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">O-glucuronidation</td>
              <td style="border:none;" align="char" char=".">2454</td>
              <td style="border:none;" align="char" char=".">0.87</td>
              <td style="border:none;" align="char" char=".">0.99</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">
                <bold>O-phosphorylation</bold>
              </td>
              <td style="border:none;" align="char" char=".">
                <bold>178</bold>
              </td>
              <td style="border:none;" align="char" char=".">
                <bold>0.99</bold>
              </td>
              <td style="border:none;" align="char" char=".">
                <bold>0.99</bold>
              </td>
            </tr>
            <tr>
              <td style="border:none;" align="left">O-sulfation</td>
              <td style="border:none;" align="char" char=".">764</td>
              <td style="border:none;" align="char" char=".">0.90</td>
              <td style="border:none;" align="char" char=".">0.99</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">S-oxidation</td>
              <td style="border:none;" align="char" char=".">96</td>
              <td style="border:none;" align="char" char=".">0.94</td>
              <td style="border:none;" align="char" char=".">0.99</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
    </sec>
    <sec id="sec2.2">
      <label>2.2</label>
      <title>Biological Activity Spectrum
Estimation</title>
      <p>The PASS software is used for the estimation of
the biological
activity spectrum (BAS) for the parent compounds and their generated
metabolites. MetaTox 2.0 uses the model containing more than 1.5 million
molecules and covering over 1900 types of biological activity predicted
with an average IAP exceeding 0.97, calculated by leave-one-out cross-validation
(LOO CV) (see, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsomega.3c06119/suppl_file/ao3c06119_si_001.pdf">Table S1</ext-link> in the Supporting
Information).</p>
      <p>For any compound from the generated metabolic
networks, three values (Pa, Pi, and Pa_max) are calculated for each
biological activity. Pa (probability “to be active”)
and Pi (probability “to be inactive”) estimate the belonging
of the predicted compound to the classes of active and inactive compounds,
respectively. Pa_max value is the maximum Pa value among all Pa values
calculated for the parent compound and its metabolites. For convenience
of use, the predicted activities are grouped by the category of biological
activity (<xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref>).</p>
      <table-wrap id="tbl2" position="float">
        <label>Table 2</label>
        <caption>
          <title>Category of Biological Activity Used
in MetaTox 2.0<xref rid="t2fn1" ref-type="table-fn">a</xref></title>
        </caption>
        <table frame="hsides" rules="groups" border="0">
          <colgroup>
            <col align="left"/>
            <col align="char" char="."/>
            <col align="char" char="."/>
          </colgroup>
          <thead>
            <tr>
              <th style="border:none;" align="center">category of biological
activity</th>
              <th style="border:none;" align="center" char=".">
                <italic>N</italic>
                <sub>act</sub>
              </th>
              <th style="border:none;" align="center" char=".">IAP<sub>avr</sub></th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td style="border:none;" align="left">antitargets</td>
              <td style="border:none;" align="char" char=".">138</td>
              <td style="border:none;" align="char" char=".">0.98</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">gene expression regulation</td>
              <td style="border:none;" align="char" char=".">14</td>
              <td style="border:none;" align="char" char=".">0.93</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">mechanisms of action</td>
              <td style="border:none;" align="char" char=".">979</td>
              <td style="border:none;" align="char" char=".">0.98</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">metabolism-related actions</td>
              <td style="border:none;" align="char" char=".">45</td>
              <td style="border:none;" align="char" char=".">0.93</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">pharmacological effects</td>
              <td style="border:none;" align="char" char=".">291</td>
              <td style="border:none;" align="char" char=".">0.95</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">toxic and adverse effects</td>
              <td style="border:none;" align="char" char=".">28</td>
              <td style="border:none;" align="char" char=".">0.94</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">transporters-related actions</td>
              <td style="border:none;" align="char" char=".">36</td>
              <td style="border:none;" align="char" char=".">0.99</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="t2fn1">
            <label>a</label>
            <p><italic>N</italic><sub>act</sub> is the total number of predicted
activities, and IAP<sub>avr</sub> is the average IAP calculated in
LOO CV for all activities in the
group.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
    </sec>
    <sec id="sec2.3">
      <label>2.3</label>
      <title>Known
Metabolic Networks’ Similarity</title>
      <p>The DrugBank v 5.1,<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> MetXBIODB,<sup><xref ref-type="bibr" rid="ref13">13</xref></sup> and
ChEMBL v. 33<sup><xref ref-type="bibr" rid="ref14">14</xref></sup> databases were used as sources
of known metabolic pathways. The
total number of pathways that were extracted: 1093 from MetXBIODB,
1013 from DrugBank v.5.1, and 173 from ChEMBL v.33. Metatox 2.0 calculates
the similarity of the original substrate (which was sent to prediction)
with parent compounds from known metabolic networks by two methods.
The first method uses the MNA (multilevel neighborhoods of atoms)
descriptors<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> and Tanimoto coefficient.
The second method uses the QNA (quantitative neighborhood of atoms)
descriptors<sup><xref ref-type="bibr" rid="ref15">15</xref></sup> and a modified Tanimoto coefficient.</p>
    </sec>
    <sec id="sec2.4">
      <label>2.4</label>
      <title>Web Application Development</title>
      <p>The PHP
and Python programming languages were used to develop the server side
of the web application. The vis.js library was used for visualizing
metabolism graphs. HTML, CSS, PHP, and JavaScript were used for the
creation of a web interface (see <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>). The generated graph of metabolism is located
on the left side of the interface. There is a menu on the right side
of the interface, which contains three links to (1) the similarity
table; (2) the aggregated BAS prediction for the selected compound;
(3) detailed information about the compounds; and the button to save
the results in SDF formats.</p>
      <fig id="fig2" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Generated schema of metabolism for irinotecan.
The aggregated profile
of the biological activity of irinotecan is shown on the right side.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao3c06119_0002" id="gr2" position="float"/>
      </fig>
    </sec>
  </sec>
  <sec id="sec3">
    <label>3</label>
    <title>Results and Discussion</title>
    <p>We have created MetaTox 2.0—a new version of the web application
MetaTox, which was initially created for the prediction of xenobiotics’
metabolites. To avoid server load, we have limited the number of metabolites
generated at each level to 10. The new features include aggregated
BAS predictions for pharmaceutical substances and their possible metabolites;
it is also possible to search for compounds with a known metabolic
network that is similar to the compounds submitted for prediction.
An additional feature is the ability to create or draw any metabolic
network and immediately receive the aggregated BAS predictions for
all nodes (compounds) of the network.</p>
    <p>The aggregation of BAS
predictions is performed for all metabolites
of the studied substrate. The prediction result is a table containing
the list of activities and three values (Pa, Pi, and Pa_max) for each
biological activity type. Table rows are highlighted, depending on
the prediction. For example, if the activity is not predicted for
the parent compound (Pa &lt; Pi) but is predicted for its metabolite
(Pa &gt; Pi), the gray color is used for this row. If the activity
is
predicted for the parent compound (Pa &gt; Pi), but the probability
“to
be active” for metabolites is higher (Pa_max &gt; Pa), then
the
brown color is used for this row.</p>
    <p>The next implemented feature
is the calculation of the similarity
to approved drugs and drugs with known metabolic networks. The data
set of known metabolic networks contains more than 2000 graphs of
metabolism from DrugBank, MetXBIODB, and ChEMBL. The structural formula
of the substrate, which is used as a query, is compared with the structures
of parent compounds from the known metabolic networks. The final tables
contain structures and similarity indexes calculated by two methods.
Depending on the selected data set, clicking on a structure will display
the complete known metabolic pathway on the left side of the interface.</p>
    <sec id="sec3.1">
      <label>3.1</label>
      <title>Example of the Web Application Utilization</title>
      <p>The schema
of the generated metabolic network of irinotecan by
MetaTox 2.0 is shown as an example in <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref> (all parameters for generation are selected
by default).</p>
      <p>The user can see the aggregated profile of the
biological activity of irinotecan, which is represented in the form
of a table and grouped into seven categories (activity category).
It is also possible to see how a specific biological activity is predicted.
To obtain this information, the user can start typing the name of
the activity into the field in the upper right corner and then select
the desired activity from the list, which includes only activities
containing a search substring. Users can set up a threshold in the
adjacent field and then click the search button. In <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>, green rectangles with Pa
values appear next to the compounds that have topoisomerase I activity
with Pa &gt;0.8.</p>
      <p>It is known that irinotecan undergoes hydrolysis
with the formation
of the active metabolite SN-38,<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> which
is over 1000 times more potent inhibitor of topoisomerase 1.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> As one can see in <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>, the metabolite SN-38 (metabolite no. 6)
has a higher probability to be a topoisomerase I inhibitor than irinotecan.
A higher probability of biological activity for the metabolite serves
as a signal for a more detailed study of this activity in the parent
compound, since in the case of high concentrations of the metabolite,
this biological activity may play a significant role in the drug effect.</p>
      <p>In addition to generating potential metabolites, users can draw
their own scheme. To do this, the user should go to the section “Make
a new schema” and then select the “Generate New”
option (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>).
To add nodes to the metabolic network, one should enter SMILES and
the names (labels) of substances. If SMILES is correct, the figure
with the substance structure appears after entering “save”.
After clicking on this figure, the user can see the BAS prediction.
Without adding edges, the user receives the BAS prediction only for
the compound itself (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>A). After adding edges, the user receives the BAS prediction,
taking into account all of the metabolites (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>B). For working with the drawn-up schema
in the future, one should remember the task ID and input it into the
corresponding field in the section “Make a new schema”
(<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>).</p>
      <fig id="fig3" position="float">
        <label>Figure 3</label>
        <caption>
          <p>Process of
drawing up a new metabolic schema.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao3c06119_0003" id="gr3" position="float"/>
      </fig>
    </sec>
  </sec>
  <sec id="sec4">
    <label>4</label>
    <title>Conclusions</title>
    <p>The developed MetaTox 2.0 web
application allows the user to generate
probable metabolites or draw up any metabolic network. For any substance
in the network, the user receives a high-precision estimation of the
biological activity profile of a compound, taking into account its
metabolites.</p>
    <p>MetaTox 2.0 provides a valuable resource for researchers
to predict
the metabolic fate of xenobiotics and investigate their potential
efficacy and toxicity effects based on their metabolism, which in
turn could help to identify the most promising compounds for experimental
studies.</p>
  </sec>
</body>
<back>
  <notes id="notes1" notes-type="si">
    <title>Supporting Information Available</title>
    <p>The Supporting Information
is
available free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acsomega.3c06119?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsomega.3c06119</ext-link>.<list id="silist" list-type="simple"><list-item><p>1,957 types of biological
activity predicted by PASS
software (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsomega.3c06119/suppl_file/ao3c06119_si_001.pdf">PDF</ext-link>)</p></list-item></list></p>
  </notes>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material content-type="local-data" id="sifile1">
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao3c06119_si_001.pdf">
        <caption>
          <p>ao3c06119_si_001.pdf</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
  <notes notes-type="" id="notes3">
    <title>Author Contributions</title>
    <p>V.P. initiated
the project. A.D. and A.R. created models for metabolism prediction.
A.R. implemented the code of the web application. D.F. and A.L. created
models for biological activity prediction. A.R. wrote the paper with
constant supervision and feedback from the coauthors. All authors
read, edited, and approved the final manuscript.</p>
  </notes>
  <notes notes-type="COI-statement" id="notes2">
    <p>The
authors
declare no competing financial interest.</p>
  </notes>
  <notes notes-type="" id="notes4">
    <title>Notes</title>
    <p>The MetaTox
2.0 web application is freely available
for query at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.way2drug.com/metatox">https://www.way2drug.com/metatox</uri>.</p>
  </notes>
  <ack>
    <title>Acknowledgments</title>
    <p>The study was carried
out within the framework of
the Russian Science Foundation, project no. 19-15-00396, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://rscf.ru/project/19-15-00396/">https://rscf.ru/project/19-15-00396/</uri>.</p>
  </ack>
  <ref-list>
    <title>References</title>
    <ref id="ref1">
      <mixed-citation publication-type="journal" id="cit1"><name><surname>Baillie</surname><given-names>T. A.</given-names></name>; <name><surname>Rettie</surname><given-names>A. E.</given-names></name><article-title>Role of Biotransformation in Drug-Induced Toxicity :
Influence of Intra- and Inter-Species Differences in Drug Metabolism</article-title>. <source>Drug Metab. Pharmacokinet.</source><year>2011</year>, <volume>26</volume> (<issue>1</issue>), <fpage>15</fpage>–<lpage>29</lpage>. <pub-id pub-id-type="doi">10.2133/dmpk.DMPK-10-RV-089</pub-id>.<pub-id pub-id-type="pmid">20978360</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref2">
      <mixed-citation publication-type="journal" id="cit2"><name><surname>Obach</surname><given-names>R. S.</given-names></name><article-title>Pharmacologically
active drug metabolites: impact on drug discovery and pharmacotherapy</article-title>. <source>Pharmacol. Rev.</source><year>2013</year>, <volume>65</volume> (<issue>2</issue>), <fpage>578</fpage>–<lpage>640</lpage>. <pub-id pub-id-type="doi">10.1124/pr.111.005439</pub-id>.<pub-id pub-id-type="pmid">23406671</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref3">
      <mixed-citation publication-type="journal" id="cit3"><name><surname>Sindelar</surname><given-names>M.</given-names></name>; <name><surname>Patti</surname><given-names>G. J.</given-names></name><article-title>Chemical Discovery in the Era of Metabolomics</article-title>. <source>J. Am. Chem. Soc.</source><year>2020</year>, <volume>142</volume> (<issue>20</issue>), <fpage>9097</fpage>–<lpage>9105</lpage>. <pub-id pub-id-type="doi">10.1021/jacs.9b13198</pub-id>.<pub-id pub-id-type="pmid">32275430</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref4">
      <mixed-citation publication-type="journal" id="cit4"><name><surname>de
Bruyn Kops</surname><given-names>C.</given-names></name>; <name><surname>Šícho</surname><given-names>M.</given-names></name>; <name><surname>Mazzolari</surname><given-names>A.</given-names></name>; <name><surname>Kirchmair</surname><given-names>J.</given-names></name><article-title>GLORYx: Prediction of the Metabolites Resulting from
Phase 1 and Phase 2 Biotransformations of Xenobiotics</article-title>. <source>Chem. Res. Toxicol.</source><year>2021</year>, <volume>34</volume> (<issue>2</issue>), <fpage>286</fpage>–<lpage>299</lpage>. <pub-id pub-id-type="doi">10.1021/acs.chemrestox.0c00224</pub-id>.<pub-id pub-id-type="pmid">32786543</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref5">
      <mixed-citation publication-type="journal" id="cit5"><name><surname>Flynn</surname><given-names>N. R.</given-names></name>; <name><surname>Dang</surname><given-names>N. L.</given-names></name>; <name><surname>Ward</surname><given-names>M. D.</given-names></name>; <name><surname>Swamidass</surname><given-names>S. J.</given-names></name><article-title>XenoNet:
Inference and Likelihood of Intermediate Metabolite Formation</article-title>. <source>J. Chem. Inf. Model.</source><year>2020</year>, <volume>60</volume> (<issue>7</issue>), <fpage>3431</fpage>–<lpage>3449</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.0c00361</pub-id>.<pub-id pub-id-type="pmid">32525671</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref6">
      <mixed-citation publication-type="journal" id="cit6"><name><surname>Hughes</surname><given-names>T. B.</given-names></name>; <name><surname>Dang</surname><given-names>N. L.</given-names></name>; <name><surname>Kumar</surname><given-names>A.</given-names></name>; <name><surname>Flynn</surname><given-names>N. R.</given-names></name>; <name><surname>Swamidass</surname><given-names>S. J.</given-names></name><article-title>Metabolic
Forest: Predicting the Diverse Structures of Drug Metabolites</article-title>. <source>J. Chem. Inf. Model.</source><year>2020</year>, <volume>60</volume> (<issue>10</issue>), <fpage>4702</fpage>–<lpage>4716</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.0c00360</pub-id>.<pub-id pub-id-type="pmid">32881497</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref7">
      <mixed-citation publication-type="journal" id="cit7"><name><surname>Rudik</surname><given-names>A. V.</given-names></name>; <name><surname>Bezhentsev</surname><given-names>V. M.</given-names></name>; <name><surname>Dmitriev</surname><given-names>A. V.</given-names></name>; <name><surname>Druzhilovskiy</surname><given-names>D. S.</given-names></name>; <name><surname>Lagunin</surname><given-names>A. A.</given-names></name>; <name><surname>Filimonov</surname><given-names>D. A.</given-names></name>; <name><surname>Poroikov</surname><given-names>V. V.</given-names></name><article-title>MetaTox: Web Application
for Predicting Structure and Toxicity of Xenobiotics’ Metabolites</article-title>. <source>J. Chem. Inf. Model.</source><year>2017</year>, <volume>57</volume> (<issue>4</issue>), <fpage>638</fpage>–<lpage>642</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.6b00662</pub-id>.<pub-id pub-id-type="pmid">28345905</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref8">
      <mixed-citation publication-type="journal" id="cit8"><name><surname>Filimonov</surname><given-names>D.</given-names></name>; <name><surname>Druzhilovskiy</surname><given-names>D.</given-names></name>; <name><surname>Lagunin</surname><given-names>A.</given-names></name>; <name><surname>Gloriozova</surname><given-names>T.</given-names></name>; <name><surname>Rudik</surname><given-names>A.</given-names></name>; <name><surname>Dmitriev</surname><given-names>A.</given-names></name>; <name><surname>Pogodin</surname><given-names>P.</given-names></name>; <name><surname>Poroikov</surname><given-names>V.</given-names></name><article-title>Computer-aided
prediction of biological activity spectra for chemical compounds:
opportunities and limitation</article-title>. <source>Biomed. Chem.</source><year>2018</year>, <volume>1</volume> (<issue>1</issue>), <elocation-id>e00004</elocation-id><pub-id pub-id-type="doi">10.18097/BMCRM00004</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref9">
      <mixed-citation publication-type="journal" id="cit9"><name><surname>Lagunin</surname><given-names>A.</given-names></name>; <name><surname>Zakharov</surname><given-names>A.</given-names></name>; <name><surname>Filimonov</surname><given-names>D.</given-names></name>; <name><surname>Poroikov</surname><given-names>V.</given-names></name><article-title>QSAR Modelling of Rat
Acute Toxicity on the Basis of PASS Prediction</article-title>. <source>Mol. Inf.</source><year>2011</year>, <volume>30</volume> (<issue>2–3</issue>), <fpage>241</fpage>–<lpage>250</lpage>. <pub-id pub-id-type="doi">10.1002/minf.201000151</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref10">
      <mixed-citation publication-type="journal" id="cit10"><name><surname>Rudik</surname><given-names>A.</given-names></name>; <name><surname>Bezhentsev</surname><given-names>V.</given-names></name>; <name><surname>Dmitriev</surname><given-names>A.</given-names></name>; <name><surname>Lagunin</surname><given-names>A.</given-names></name>; <name><surname>Filimonov</surname><given-names>D.</given-names></name>; <name><surname>Poroikov</surname><given-names>V.</given-names></name><article-title>Metatox - Web application for generation of metabolic
pathways and toxicity estimation</article-title>. <source>J. Bioinf.
Comput. Biol.</source><year>2019</year>, <volume>17</volume> (<issue>01</issue>), <fpage>1940001</fpage><pub-id pub-id-type="doi">10.1142/S0219720019400018</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref11">
      <mixed-citation publication-type="journal" id="cit11"><name><surname>Filimonov</surname><given-names>D. A.</given-names></name>; <name><surname>Druzhilovskiy</surname><given-names>D. S.</given-names></name>; <name><surname>Lagunin</surname><given-names>A. A.</given-names></name>; <name><surname>Gloriozova</surname><given-names>T. A.</given-names></name>; <name><surname>Rudik</surname><given-names>A. V.</given-names></name>; <name><surname>Dmitriev</surname><given-names>A. V.</given-names></name>; <name><surname>Pogodin</surname><given-names>P.</given-names></name>; <name><surname>Poroikov</surname><given-names>V.</given-names></name><article-title>Computer-aided
prediction of biological activity spectra for chemical compounds:
opportunities and limitation</article-title>. <source>Biomed. Chem.</source><year>2018</year>, <volume>1</volume>, <elocation-id>e00004</elocation-id><pub-id pub-id-type="doi">10.18097/BMCRM00004</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref12">
      <mixed-citation publication-type="journal" id="cit12"><name><surname>Wishart</surname><given-names>D. S.</given-names></name>; <name><surname>Feunang</surname><given-names>Y. D.</given-names></name>; <name><surname>Guo</surname><given-names>A. C.</given-names></name>; <name><surname>Lo</surname><given-names>E. J.</given-names></name>; <name><surname>Marcu</surname><given-names>A.</given-names></name>; <name><surname>Grant</surname><given-names>J. R.</given-names></name>; <name><surname>Sajed</surname><given-names>T.</given-names></name>; <name><surname>Johnson</surname><given-names>D.</given-names></name>; <name><surname>Li</surname><given-names>C.</given-names></name>; <name><surname>Sayeeda</surname><given-names>Z.</given-names></name>; <name><surname>Assempour</surname><given-names>N.</given-names></name>; <name><surname>Iynkkaran</surname><given-names>I.</given-names></name>; <name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>Maciejewski</surname><given-names>A.</given-names></name>; <name><surname>Gale</surname><given-names>N.</given-names></name>; <name><surname>Wilson</surname><given-names>A.</given-names></name>; <name><surname>Chin</surname><given-names>L.</given-names></name>; <name><surname>Cummings</surname><given-names>R.</given-names></name>; <name><surname>Le</surname><given-names>D.</given-names></name>; <name><surname>Pon</surname><given-names>A.</given-names></name>; <name><surname>Knox</surname><given-names>C.</given-names></name>; et al. <article-title>DrugBank 5.0: a major update to the DrugBank database for 2018</article-title>. <source>Nucleic Acids Res.</source><year>2018</year>, <volume>46</volume> (<issue>D1</issue>), <fpage>D1074</fpage>–<lpage>D1082</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkx1037</pub-id>.<pub-id pub-id-type="pmid">29126136</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref13">
      <mixed-citation publication-type="journal" id="cit13"><name><surname>Djoumbou-Feunang</surname><given-names>Y.</given-names></name>; <name><surname>Fiamoncini</surname><given-names>J.</given-names></name>; <name><surname>Gil-de-la-Fuente</surname><given-names>A.</given-names></name>; <name><surname>Greiner</surname><given-names>R.</given-names></name>; <name><surname>Manach</surname><given-names>C.</given-names></name>; <name><surname>Wishart</surname><given-names>D. S.</given-names></name><article-title>BioTransformer: a comprehensive computational tool
for small molecule metabolism prediction and metabolite identification</article-title>. <source>J. Cheminf.</source><year>2019</year>, <volume>11</volume> (<issue>1</issue>), <fpage>2</fpage><pub-id pub-id-type="doi">10.1186/s13321-018-0324-5</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref14">
      <mixed-citation publication-type="journal" id="cit14"><name><surname>Mendez</surname><given-names>D.</given-names></name>; <name><surname>Gaulton</surname><given-names>A.</given-names></name>; <name><surname>Bento</surname><given-names>A. P.</given-names></name>; <name><surname>Chambers</surname><given-names>J.</given-names></name>; <name><surname>De Veij</surname><given-names>M.</given-names></name>; <name><surname>Félix</surname><given-names>E.</given-names></name>; <name><surname>Magariños</surname><given-names>M.</given-names></name>; <name><surname>Mosquera</surname><given-names>J. F.</given-names></name>; <name><surname>Mutowo</surname><given-names>P.</given-names></name>; <name><surname>Nowotka</surname><given-names>M.</given-names></name>; <name><surname>Gordillo-Marañón</surname><given-names>M.</given-names></name>; <name><surname>Hunter</surname><given-names>F.</given-names></name>; <name><surname>Junco</surname><given-names>L.</given-names></name>; <name><surname>Mugumbate</surname><given-names>G.</given-names></name>; <name><surname>Rodriguez-Lopez</surname><given-names>M.</given-names></name>; <name><surname>Atkinson</surname><given-names>F.</given-names></name>; <name><surname>Bosc</surname><given-names>N.</given-names></name>; <name><surname>Radoux</surname><given-names>C. J.</given-names></name>; <name><surname>Segura-Cabrera</surname><given-names>A.</given-names></name>; <name><surname>Hersey</surname><given-names>A.</given-names></name>; <name><surname>Leach</surname><given-names>A. R.</given-names></name><article-title>ChEMBL:
towards
direct deposition of bioassay data</article-title>. <source>Nucleic
Acids Res.</source><year>2019</year>, <volume>47</volume> (<issue>D1</issue>), <fpage>D930</fpage>–<lpage>D940</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gky1075</pub-id>.<pub-id pub-id-type="pmid">30398643</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref15">
      <mixed-citation publication-type="journal" id="cit15"><name><surname>Filimonov</surname><given-names>D.</given-names></name>; <name><surname>Zakharov</surname><given-names>A.</given-names></name>; <name><surname>Lagunin</surname><given-names>A.</given-names></name>; <name><surname>Poroikov</surname><given-names>V.</given-names></name><article-title>QNA-based “Star
Track” QSAR approach</article-title>. <source>SAR QSAR Environ.
Res.</source><year>2009</year>, <volume>20</volume> (<issue>7–8</issue>), <fpage>679</fpage>–<lpage>709</lpage>. <pub-id pub-id-type="doi">10.1080/10629360903438370</pub-id>.<pub-id pub-id-type="pmid">20024804</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref16">
      <mixed-citation publication-type="journal" id="cit16"><name><surname>Kawato</surname><given-names>Y.</given-names></name>; <name><surname>Aonuma</surname><given-names>M.</given-names></name>; <name><surname>Hirota</surname><given-names>Y.</given-names></name>; <name><surname>Kuga</surname><given-names>H.</given-names></name>; <name><surname>Sato</surname><given-names>K.</given-names></name><article-title>Intracellular
roles of SN-38, a metabolite of the camptothecin derivative CPT-11,
in the antitumor effect of CPT-11</article-title>. <source>Cancer Res.</source><year>1991</year>, <volume>51</volume> (<issue>16</issue>), <fpage>4187</fpage>–<lpage>4191</lpage>.<pub-id pub-id-type="pmid">1651156</pub-id>
</mixed-citation>
    </ref>
  </ref-list>
</back>
<?properties open_access?>
<?DTDIdentifier.IdentifierValue -//ACS//DTD ACS Journal DTD v1.02 20061031//EN?>
<?DTDIdentifier.IdentifierType public?>
<?SourceDTD.DTDName ACSJournal-v102.dtd?>
<?SourceDTD.Version 1.02?>
<?ConverterInfo.XSLTName acs2nlmx2.xsl?>
<?ConverterInfo.Version 1?>
<processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
  <restricted-by>pmc</restricted-by>
</processing-meta>
<front>
  <journal-meta>
    <journal-id journal-id-type="nlm-ta">ACS Omega</journal-id>
    <journal-id journal-id-type="iso-abbrev">ACS Omega</journal-id>
    <journal-id journal-id-type="publisher-id">ao</journal-id>
    <journal-id journal-id-type="coden">acsodf</journal-id>
    <journal-title-group>
      <journal-title>ACS Omega</journal-title>
    </journal-title-group>
    <issn pub-type="epub">2470-1343</issn>
    <publisher>
      <publisher-name>American Chemical Society</publisher-name>
    </publisher>
  </journal-meta>
  <article-meta>
    <article-id pub-id-type="pmcid">10702315</article-id>
    <article-id pub-id-type="doi">10.1021/acsomega.3c06119</article-id>
    <article-categories>
      <subj-group>
        <subject>Article</subject>
      </subj-group>
    </article-categories>
    <title-group>
      <article-title>MetaTox 2.0: Estimating the
Biological Activity Spectra of Drug-like
Compounds Taking into Account Probable Biotransformations</article-title>
    </title-group>
    <contrib-group>
      <contrib contrib-type="author" corresp="yes" id="ath1">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-8916-9675</contrib-id>
        <name>
          <surname>Rudik</surname>
          <given-names>Anastasia V.</given-names>
        </name>
        <xref rid="cor1" ref-type="other">*</xref>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <contrib contrib-type="author" id="ath2">
        <name>
          <surname>Dmitriev</surname>
          <given-names>Alexander V.</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <contrib contrib-type="author" id="ath3">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-1757-8004</contrib-id>
        <name>
          <surname>Lagunin</surname>
          <given-names>Alexey A.</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
        <xref rid="aff2" ref-type="aff">‡</xref>
      </contrib>
      <contrib contrib-type="author" id="ath4">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-0339-8478</contrib-id>
        <name>
          <surname>Filimonov</surname>
          <given-names>Dmitry A.</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <contrib contrib-type="author" id="ath5">
        <contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0001-7937-2621</contrib-id>
        <name>
          <surname>Poroikov</surname>
          <given-names>Vladimir V.</given-names>
        </name>
        <xref rid="aff1" ref-type="aff">†</xref>
      </contrib>
      <aff id="aff1"><label>†</label>Department
of Bioinformatics, <institution>Institute of Biomedical
Chemistry</institution>, 10 Bldg. 8,
Pogodinskaya Str., Moscow 119121, <country>Russia</country></aff>
      <aff id="aff2"><label>‡</label>Department
of Bioinformatics, <institution>Pirogov Russian National
Research Medical University</institution>, 1 Ostrovityanova Str., Moscow 117997, <country>Russia</country></aff>
    </contrib-group>
    <author-notes>
      <corresp id="cor1"><label>*</label>Email: <email>rudik_anastassia@mail.ru</email>.</corresp>
    </author-notes>
    <pub-date pub-type="epub">
      <day>23</day>
      <month>11</month>
      <year>2023</year>
    </pub-date>
    <pub-date pub-type="collection">
      <day>05</day>
      <month>12</month>
      <year>2023</year>
    </pub-date>
    <volume>8</volume>
    <issue>48</issue>
    <fpage>45774</fpage>
    <lpage>45778</lpage>
    <history>
      <date date-type="received">
        <day>28</day>
        <month>08</month>
        <year>2023</year>
      </date>
      <date date-type="accepted">
        <day>15</day>
        <month>11</month>
        <year>2023</year>
      </date>
      <date date-type="rev-recd">
        <day>12</day>
        <month>11</month>
        <year>2023</year>
      </date>
    </history>
    <permissions>
      <copyright-statement>© 2023 The Authors. Published by American Chemical Society</copyright-statement>
      <copyright-year>2023</copyright-year>
      <copyright-holder>The Authors</copyright-holder>
      <license>
        <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
        <license-p>Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>).</license-p>
      </license>
    </permissions>
    <abstract>
      <p content-type="toc-graphic">
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao3c06119_0004" id="ab-tgr1"/>
      </p>
      <p>After the biotransformation
of xenobiotics in the human body, the
biological activity of the metabolites may differ from the activity
of parent compounds. Therefore, to assess the overall biological activity
of a drug-like compound, it is important to take into account its
metabolites and their biological activity. We developed MetaTox 2.0—an
updated version of the MetaTox web application that was able to predict
the metabolites of xenobiotics. Innovations include estimating the
biological activity profile of a compound and taking into account
its metabolites. The estimation is based on the PASS (prediction of
activity spectra for substances) algorithm and on the latest version
of the training set covering over 1900 biological activities predicted
with an average accuracy exceeding 0.97. Also, MetaTox 2.0 allows
the search for similar substances among more than 2000 drugs with
known metabolic networks, which were extracted from the ChEMBL, MetXBIODB,
and DrugBank databases. MetaTox 2.0 is freely available on the web
at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.way2drug.com/metatox">https://www.way2drug.com/metatox</uri>.</p>
    </abstract>
    <funding-group>
      <award-group>
        <funding-source>
          <institution-wrap>
            <institution>Russian Science Foundation</institution>
            <institution-id institution-id-type="doi">10.13039/501100006769</institution-id>
          </institution-wrap>
        </funding-source>
        <award-id>19-15-00396</award-id>
      </award-group>
    </funding-group>
    <custom-meta-group>
      <custom-meta>
        <meta-name>document-id-old-9</meta-name>
        <meta-value>ao3c06119</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>document-id-new-14</meta-name>
        <meta-value>ao3c06119</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>ccc-price</meta-name>
        <meta-value/>
      </custom-meta>
    </custom-meta-group>
  </article-meta>
</front>
<body>
  <sec id="sec1">
    <label>1</label>
    <title>Introduction</title>
    <p>Biotransformations of
drug-like compounds in the human body could
lead to adverse effects caused by their metabolites.<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> In addition, metabolites may interact with the same target
as the parent compound or may change the clinical outcome by acting
on some other targets.<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> During the drug
development process, it is not always possible to experimentally determine
the structures of all possible metabolites at the early stages of
research.<sup><xref ref-type="bibr" rid="ref3">3</xref></sup> To improve the safety profile
of new drugs, in silico methods may be applied to estimate the biological
activity profile, including toxicity and side effects, based on the
structural formulas of both parent compounds and their potential metabolites.</p>
    <p>There are some freely available web applications that are able
to predict possible biotransformations of xenobiotics. Some examples
include Gloryx,<sup><xref ref-type="bibr" rid="ref4">4</xref></sup> XenoNet,<sup><xref ref-type="bibr" rid="ref5">5</xref></sup> the Metabolic Forest,<sup><xref ref-type="bibr" rid="ref6">6</xref></sup> etc.
However, there is no freely available web application that allows
evaluation of the aggregated biological activity spectrum for the
parent compound based on its putative biotransformation and metabolites.</p>
    <p>Earlier, we developed the web application MetaTox,<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> which was able to generate possible xenobiotics metabolic
pathways in the human organism. The assessment of the generated metabolite
probability formation is based on the biotransformation reactions’
probabilities aggregated with an estimation of a place in the molecule
where the metabolic reaction occurs. The MetaTox algorithm is based
on the Naive Bayes classifier implemented in the PASS (prediction
of activity spectra for substances) software.<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> The generated possible metabolic network was visualized as a tree,
and for each node (compound) on the tree, acute toxicity values (LD<sub>50</sub>) for rats in four types of administrations<sup><xref ref-type="bibr" rid="ref9">9</xref></sup> were predicted.</p>
    <p>Here, we represent a new version
of MetaTox (MetaTox 2.0), in which
we have implemented some essential novel features. The innovations
are presented as gray rectangles in <xref rid="fig1" ref-type="fig">Figure <xref rid="fig1" ref-type="fig">1</xref></xref>. The first one is the aggregation mechanism
of the biological activity profile prediction for the compound, taking
into account the prediction for all its metabolites. The second one
is searching for compounds similar to the parent compound among the
drugs with known metabolic networks, and the third one is the creation
(drawing) of any metabolic networks with subsequent estimation of
the aggregated profile of biological activity for all network nodes.</p>
    <fig id="fig1" position="float">
      <label>Figure 1</label>
      <caption>
        <p>Scheme
of MetaTox 2.0.</p>
      </caption>
      <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao3c06119_0001" id="gr1" position="float"/>
    </fig>
  </sec>
  <sec id="sec2">
    <label>2</label>
    <title>Materials and Methods</title>
    <sec id="sec2.1">
      <label>2.1</label>
      <title>Metabolic Network Estimation</title>
      <p>The
algorithm, which is implemented in MetaTox 2.0 for the generation
and assessment of metabolites, remained the same as that published
earlier.<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> MetaTox 2.0 generates metabolites
for 19 biotransformation reactions (the first version of MetaTox predicted
nine biotransformation reactions,<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> its
update in the year 2019 included 15 biotransformation reactions<sup><xref ref-type="bibr" rid="ref10">10</xref></sup>). A complete list of MetaTox biotransformation
reactions and their characteristics in the training set are represented
in <xref rid="tbl1" ref-type="other">Table <xref rid="tbl1" ref-type="other">1</xref></xref>. The reactions
that were added compared to the publication of Rudik with coauthors<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> are bolded. The training sets for the models
predicting the previously published biotransformation reactions<sup><xref ref-type="bibr" rid="ref10">10</xref></sup> were also updated. To estimate the accuracy
of the prediction models, we used the invariant accuracy of prediction
(IAP) calculated by the leave-one-out cross-validation (LOO CV) procedure.
The IAP parameter is equivalent to the ROC AUC.<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> The IAP<sub>reaction</sub> is the IAP calculated for the
models, which were used to estimate the probability that a compound
would undergo a given biotransformation reaction. The IAP<sub>SOM</sub> is the IAP calculated for the models, which are used to estimate
the probability that a concerned atom would be a site of metabolism
(SOM) of a given biotransformation reaction, and <italic>N</italic><sub>comp</sub> is the number of compounds in the training set.</p>
      <table-wrap id="tbl1" position="float">
        <label>Table 1</label>
        <caption>
          <title>List of Biotransformation Reactions
Presented in MetaTox 2.0</title>
        </caption>
        <table frame="hsides" rules="groups" border="0">
          <colgroup>
            <col align="left"/>
            <col align="char" char="."/>
            <col align="char" char="."/>
            <col align="char" char="."/>
          </colgroup>
          <thead>
            <tr>
              <th style="border:none;" align="center">biotransformation
reactions</th>
              <th style="border:none;" align="center" char=".">
                <italic>N</italic>
                <sub>comp</sub>
              </th>
              <th style="border:none;" align="center" char=".">IAP<sub>reaction</sub></th>
              <th style="border:none;" align="center" char=".">IAP<sub>SOM</sub></th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td style="border:none;" align="left">aliphatic hydroxylation</td>
              <td style="border:none;" align="char" char=".">407</td>
              <td style="border:none;" align="char" char=".">0.82</td>
              <td style="border:none;" align="char" char=".">0.91</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">aromatic hydroxylation</td>
              <td style="border:none;" align="char" char=".">322</td>
              <td style="border:none;" align="char" char=".">0.84</td>
              <td style="border:none;" align="char" char=".">0.92</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">C-oxidation</td>
              <td style="border:none;" align="char" char=".">145</td>
              <td style="border:none;" align="char" char=".">0.80</td>
              <td style="border:none;" align="char" char=".">0.86</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">dehydrogenation</td>
              <td style="border:none;" align="char" char=".">119</td>
              <td style="border:none;" align="char" char=".">0.81</td>
              <td style="border:none;" align="char" char=".">0.91</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">epoxidation</td>
              <td style="border:none;" align="char" char=".">355</td>
              <td style="border:none;" align="char" char=".">0.89</td>
              <td style="border:none;" align="char" char=".">0.93</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">glutathionylation</td>
              <td style="border:none;" align="char" char=".">477</td>
              <td style="border:none;" align="char" char=".">0.87</td>
              <td style="border:none;" align="char" char=".">0.88</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">
                <bold>hydrogenation</bold>
              </td>
              <td style="border:none;" align="char" char=".">
                <bold>580</bold>
              </td>
              <td style="border:none;" align="char" char=".">
                <bold>0.87</bold>
              </td>
              <td style="border:none;" align="char" char=".">
                <bold>0.87</bold>
              </td>
            </tr>
            <tr>
              <td style="border:none;" align="left">hydrolysis</td>
              <td style="border:none;" align="char" char=".">3220</td>
              <td style="border:none;" align="char" char=".">0.92</td>
              <td style="border:none;" align="char" char=".">0.99</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">
                <bold>methylation</bold>
              </td>
              <td style="border:none;" align="char" char=".">
                <bold>266</bold>
              </td>
              <td style="border:none;" align="char" char=".">
                <bold>0.89</bold>
              </td>
              <td style="border:none;" align="char" char=".">
                <bold>0.96</bold>
              </td>
            </tr>
            <tr>
              <td style="border:none;" align="left">N-acetylation</td>
              <td style="border:none;" align="char" char=".">351</td>
              <td style="border:none;" align="char" char=".">0.95</td>
              <td style="border:none;" align="char" char=".">0.99</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">N-dealkylation</td>
              <td style="border:none;" align="char" char=".">397</td>
              <td style="border:none;" align="char" char=".">0.93</td>
              <td style="border:none;" align="char" char=".">0.97</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">N-glucuronidation</td>
              <td style="border:none;" align="char" char=".">309</td>
              <td style="border:none;" align="char" char=".">0.91</td>
              <td style="border:none;" align="char" char=".">0.99</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">
                <bold>N-hydroxylation</bold>
              </td>
              <td style="border:none;" align="char" char=".">
                <bold>112</bold>
              </td>
              <td style="border:none;" align="char" char=".">
                <bold>0.91</bold>
              </td>
              <td style="border:none;" align="char" char=".">
                <bold>0.99</bold>
              </td>
            </tr>
            <tr>
              <td style="border:none;" align="left">N-oxidation</td>
              <td style="border:none;" align="char" char=".">115</td>
              <td style="border:none;" align="char" char=".">0.90</td>
              <td style="border:none;" align="char" char=".">0.99</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">O-dealkylation</td>
              <td style="border:none;" align="char" char=".">279</td>
              <td style="border:none;" align="char" char=".">0.90</td>
              <td style="border:none;" align="char" char=".">0.99</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">O-glucuronidation</td>
              <td style="border:none;" align="char" char=".">2454</td>
              <td style="border:none;" align="char" char=".">0.87</td>
              <td style="border:none;" align="char" char=".">0.99</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">
                <bold>O-phosphorylation</bold>
              </td>
              <td style="border:none;" align="char" char=".">
                <bold>178</bold>
              </td>
              <td style="border:none;" align="char" char=".">
                <bold>0.99</bold>
              </td>
              <td style="border:none;" align="char" char=".">
                <bold>0.99</bold>
              </td>
            </tr>
            <tr>
              <td style="border:none;" align="left">O-sulfation</td>
              <td style="border:none;" align="char" char=".">764</td>
              <td style="border:none;" align="char" char=".">0.90</td>
              <td style="border:none;" align="char" char=".">0.99</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">S-oxidation</td>
              <td style="border:none;" align="char" char=".">96</td>
              <td style="border:none;" align="char" char=".">0.94</td>
              <td style="border:none;" align="char" char=".">0.99</td>
            </tr>
          </tbody>
        </table>
      </table-wrap>
    </sec>
    <sec id="sec2.2">
      <label>2.2</label>
      <title>Biological Activity Spectrum
Estimation</title>
      <p>The PASS software is used for the estimation of
the biological
activity spectrum (BAS) for the parent compounds and their generated
metabolites. MetaTox 2.0 uses the model containing more than 1.5 million
molecules and covering over 1900 types of biological activity predicted
with an average IAP exceeding 0.97, calculated by leave-one-out cross-validation
(LOO CV) (see, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsomega.3c06119/suppl_file/ao3c06119_si_001.pdf">Table S1</ext-link> in the Supporting
Information).</p>
      <p>For any compound from the generated metabolic
networks, three values (Pa, Pi, and Pa_max) are calculated for each
biological activity. Pa (probability “to be active”)
and Pi (probability “to be inactive”) estimate the belonging
of the predicted compound to the classes of active and inactive compounds,
respectively. Pa_max value is the maximum Pa value among all Pa values
calculated for the parent compound and its metabolites. For convenience
of use, the predicted activities are grouped by the category of biological
activity (<xref rid="tbl2" ref-type="other">Table <xref rid="tbl2" ref-type="other">2</xref></xref>).</p>
      <table-wrap id="tbl2" position="float">
        <label>Table 2</label>
        <caption>
          <title>Category of Biological Activity Used
in MetaTox 2.0<xref rid="t2fn1" ref-type="table-fn">a</xref></title>
        </caption>
        <table frame="hsides" rules="groups" border="0">
          <colgroup>
            <col align="left"/>
            <col align="char" char="."/>
            <col align="char" char="."/>
          </colgroup>
          <thead>
            <tr>
              <th style="border:none;" align="center">category of biological
activity</th>
              <th style="border:none;" align="center" char=".">
                <italic>N</italic>
                <sub>act</sub>
              </th>
              <th style="border:none;" align="center" char=".">IAP<sub>avr</sub></th>
            </tr>
          </thead>
          <tbody>
            <tr>
              <td style="border:none;" align="left">antitargets</td>
              <td style="border:none;" align="char" char=".">138</td>
              <td style="border:none;" align="char" char=".">0.98</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">gene expression regulation</td>
              <td style="border:none;" align="char" char=".">14</td>
              <td style="border:none;" align="char" char=".">0.93</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">mechanisms of action</td>
              <td style="border:none;" align="char" char=".">979</td>
              <td style="border:none;" align="char" char=".">0.98</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">metabolism-related actions</td>
              <td style="border:none;" align="char" char=".">45</td>
              <td style="border:none;" align="char" char=".">0.93</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">pharmacological effects</td>
              <td style="border:none;" align="char" char=".">291</td>
              <td style="border:none;" align="char" char=".">0.95</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">toxic and adverse effects</td>
              <td style="border:none;" align="char" char=".">28</td>
              <td style="border:none;" align="char" char=".">0.94</td>
            </tr>
            <tr>
              <td style="border:none;" align="left">transporters-related actions</td>
              <td style="border:none;" align="char" char=".">36</td>
              <td style="border:none;" align="char" char=".">0.99</td>
            </tr>
          </tbody>
        </table>
        <table-wrap-foot>
          <fn id="t2fn1">
            <label>a</label>
            <p><italic>N</italic><sub>act</sub> is the total number of predicted
activities, and IAP<sub>avr</sub> is the average IAP calculated in
LOO CV for all activities in the
group.</p>
          </fn>
        </table-wrap-foot>
      </table-wrap>
    </sec>
    <sec id="sec2.3">
      <label>2.3</label>
      <title>Known
Metabolic Networks’ Similarity</title>
      <p>The DrugBank v 5.1,<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> MetXBIODB,<sup><xref ref-type="bibr" rid="ref13">13</xref></sup> and
ChEMBL v. 33<sup><xref ref-type="bibr" rid="ref14">14</xref></sup> databases were used as sources
of known metabolic pathways. The
total number of pathways that were extracted: 1093 from MetXBIODB,
1013 from DrugBank v.5.1, and 173 from ChEMBL v.33. Metatox 2.0 calculates
the similarity of the original substrate (which was sent to prediction)
with parent compounds from known metabolic networks by two methods.
The first method uses the MNA (multilevel neighborhoods of atoms)
descriptors<sup><xref ref-type="bibr" rid="ref8">8</xref></sup> and Tanimoto coefficient.
The second method uses the QNA (quantitative neighborhood of atoms)
descriptors<sup><xref ref-type="bibr" rid="ref15">15</xref></sup> and a modified Tanimoto coefficient.</p>
    </sec>
    <sec id="sec2.4">
      <label>2.4</label>
      <title>Web Application Development</title>
      <p>The PHP
and Python programming languages were used to develop the server side
of the web application. The vis.js library was used for visualizing
metabolism graphs. HTML, CSS, PHP, and JavaScript were used for the
creation of a web interface (see <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>). The generated graph of metabolism is located
on the left side of the interface. There is a menu on the right side
of the interface, which contains three links to (1) the similarity
table; (2) the aggregated BAS prediction for the selected compound;
(3) detailed information about the compounds; and the button to save
the results in SDF formats.</p>
      <fig id="fig2" position="float">
        <label>Figure 2</label>
        <caption>
          <p>Generated schema of metabolism for irinotecan.
The aggregated profile
of the biological activity of irinotecan is shown on the right side.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao3c06119_0002" id="gr2" position="float"/>
      </fig>
    </sec>
  </sec>
  <sec id="sec3">
    <label>3</label>
    <title>Results and Discussion</title>
    <p>We have created MetaTox 2.0—a new version of the web application
MetaTox, which was initially created for the prediction of xenobiotics’
metabolites. To avoid server load, we have limited the number of metabolites
generated at each level to 10. The new features include aggregated
BAS predictions for pharmaceutical substances and their possible metabolites;
it is also possible to search for compounds with a known metabolic
network that is similar to the compounds submitted for prediction.
An additional feature is the ability to create or draw any metabolic
network and immediately receive the aggregated BAS predictions for
all nodes (compounds) of the network.</p>
    <p>The aggregation of BAS
predictions is performed for all metabolites
of the studied substrate. The prediction result is a table containing
the list of activities and three values (Pa, Pi, and Pa_max) for each
biological activity type. Table rows are highlighted, depending on
the prediction. For example, if the activity is not predicted for
the parent compound (Pa &lt; Pi) but is predicted for its metabolite
(Pa &gt; Pi), the gray color is used for this row. If the activity
is
predicted for the parent compound (Pa &gt; Pi), but the probability
“to
be active” for metabolites is higher (Pa_max &gt; Pa), then
the
brown color is used for this row.</p>
    <p>The next implemented feature
is the calculation of the similarity
to approved drugs and drugs with known metabolic networks. The data
set of known metabolic networks contains more than 2000 graphs of
metabolism from DrugBank, MetXBIODB, and ChEMBL. The structural formula
of the substrate, which is used as a query, is compared with the structures
of parent compounds from the known metabolic networks. The final tables
contain structures and similarity indexes calculated by two methods.
Depending on the selected data set, clicking on a structure will display
the complete known metabolic pathway on the left side of the interface.</p>
    <sec id="sec3.1">
      <label>3.1</label>
      <title>Example of the Web Application Utilization</title>
      <p>The schema
of the generated metabolic network of irinotecan by
MetaTox 2.0 is shown as an example in <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref> (all parameters for generation are selected
by default).</p>
      <p>The user can see the aggregated profile of the
biological activity of irinotecan, which is represented in the form
of a table and grouped into seven categories (activity category).
It is also possible to see how a specific biological activity is predicted.
To obtain this information, the user can start typing the name of
the activity into the field in the upper right corner and then select
the desired activity from the list, which includes only activities
containing a search substring. Users can set up a threshold in the
adjacent field and then click the search button. In <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>, green rectangles with Pa
values appear next to the compounds that have topoisomerase I activity
with Pa &gt;0.8.</p>
      <p>It is known that irinotecan undergoes hydrolysis
with the formation
of the active metabolite SN-38,<sup><xref ref-type="bibr" rid="ref2">2</xref></sup> which
is over 1000 times more potent inhibitor of topoisomerase 1.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> As one can see in <xref rid="fig2" ref-type="fig">Figure <xref rid="fig2" ref-type="fig">2</xref></xref>, the metabolite SN-38 (metabolite no. 6)
has a higher probability to be a topoisomerase I inhibitor than irinotecan.
A higher probability of biological activity for the metabolite serves
as a signal for a more detailed study of this activity in the parent
compound, since in the case of high concentrations of the metabolite,
this biological activity may play a significant role in the drug effect.</p>
      <p>In addition to generating potential metabolites, users can draw
their own scheme. To do this, the user should go to the section “Make
a new schema” and then select the “Generate New”
option (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>).
To add nodes to the metabolic network, one should enter SMILES and
the names (labels) of substances. If SMILES is correct, the figure
with the substance structure appears after entering “save”.
After clicking on this figure, the user can see the BAS prediction.
Without adding edges, the user receives the BAS prediction only for
the compound itself (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>A). After adding edges, the user receives the BAS prediction,
taking into account all of the metabolites (<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>B). For working with the drawn-up schema
in the future, one should remember the task ID and input it into the
corresponding field in the section “Make a new schema”
(<xref rid="fig3" ref-type="fig">Figure <xref rid="fig3" ref-type="fig">3</xref></xref>).</p>
      <fig id="fig3" position="float">
        <label>Figure 3</label>
        <caption>
          <p>Process of
drawing up a new metabolic schema.</p>
        </caption>
        <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao3c06119_0003" id="gr3" position="float"/>
      </fig>
    </sec>
  </sec>
  <sec id="sec4">
    <label>4</label>
    <title>Conclusions</title>
    <p>The developed MetaTox 2.0 web
application allows the user to generate
probable metabolites or draw up any metabolic network. For any substance
in the network, the user receives a high-precision estimation of the
biological activity profile of a compound, taking into account its
metabolites.</p>
    <p>MetaTox 2.0 provides a valuable resource for researchers
to predict
the metabolic fate of xenobiotics and investigate their potential
efficacy and toxicity effects based on their metabolism, which in
turn could help to identify the most promising compounds for experimental
studies.</p>
  </sec>
</body>
<back>
  <notes id="notes1" notes-type="si">
    <title>Supporting Information Available</title>
    <p>The Supporting Information
is
available free of charge at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/10.1021/acsomega.3c06119?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsomega.3c06119</ext-link>.<list id="silist" list-type="simple"><list-item><p>1,957 types of biological
activity predicted by PASS
software (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://pubs.acs.org/doi/suppl/10.1021/acsomega.3c06119/suppl_file/ao3c06119_si_001.pdf">PDF</ext-link>)</p></list-item></list></p>
  </notes>
  <sec sec-type="supplementary-material">
    <title>Supplementary Material</title>
    <supplementary-material content-type="local-data" id="sifile1">
      <media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="ao3c06119_si_001.pdf">
        <caption>
          <p>ao3c06119_si_001.pdf</p>
        </caption>
      </media>
    </supplementary-material>
  </sec>
  <notes notes-type="" id="notes3">
    <title>Author Contributions</title>
    <p>V.P. initiated
the project. A.D. and A.R. created models for metabolism prediction.
A.R. implemented the code of the web application. D.F. and A.L. created
models for biological activity prediction. A.R. wrote the paper with
constant supervision and feedback from the coauthors. All authors
read, edited, and approved the final manuscript.</p>
  </notes>
  <notes notes-type="COI-statement" id="notes2">
    <p>The
authors
declare no competing financial interest.</p>
  </notes>
  <notes notes-type="" id="notes4">
    <title>Notes</title>
    <p>The MetaTox
2.0 web application is freely available
for query at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.way2drug.com/metatox">https://www.way2drug.com/metatox</uri>.</p>
  </notes>
  <ack>
    <title>Acknowledgments</title>
    <p>The study was carried
out within the framework of
the Russian Science Foundation, project no. 19-15-00396, <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://rscf.ru/project/19-15-00396/">https://rscf.ru/project/19-15-00396/</uri>.</p>
  </ack>
  <ref-list>
    <title>References</title>
    <ref id="ref1">
      <mixed-citation publication-type="journal" id="cit1"><name><surname>Baillie</surname><given-names>T. A.</given-names></name>; <name><surname>Rettie</surname><given-names>A. E.</given-names></name><article-title>Role of Biotransformation in Drug-Induced Toxicity :
Influence of Intra- and Inter-Species Differences in Drug Metabolism</article-title>. <source>Drug Metab. Pharmacokinet.</source><year>2011</year>, <volume>26</volume> (<issue>1</issue>), <fpage>15</fpage>–<lpage>29</lpage>. <pub-id pub-id-type="doi">10.2133/dmpk.DMPK-10-RV-089</pub-id>.<pub-id pub-id-type="pmid">20978360</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref2">
      <mixed-citation publication-type="journal" id="cit2"><name><surname>Obach</surname><given-names>R. S.</given-names></name><article-title>Pharmacologically
active drug metabolites: impact on drug discovery and pharmacotherapy</article-title>. <source>Pharmacol. Rev.</source><year>2013</year>, <volume>65</volume> (<issue>2</issue>), <fpage>578</fpage>–<lpage>640</lpage>. <pub-id pub-id-type="doi">10.1124/pr.111.005439</pub-id>.<pub-id pub-id-type="pmid">23406671</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref3">
      <mixed-citation publication-type="journal" id="cit3"><name><surname>Sindelar</surname><given-names>M.</given-names></name>; <name><surname>Patti</surname><given-names>G. J.</given-names></name><article-title>Chemical Discovery in the Era of Metabolomics</article-title>. <source>J. Am. Chem. Soc.</source><year>2020</year>, <volume>142</volume> (<issue>20</issue>), <fpage>9097</fpage>–<lpage>9105</lpage>. <pub-id pub-id-type="doi">10.1021/jacs.9b13198</pub-id>.<pub-id pub-id-type="pmid">32275430</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref4">
      <mixed-citation publication-type="journal" id="cit4"><name><surname>de
Bruyn Kops</surname><given-names>C.</given-names></name>; <name><surname>Šícho</surname><given-names>M.</given-names></name>; <name><surname>Mazzolari</surname><given-names>A.</given-names></name>; <name><surname>Kirchmair</surname><given-names>J.</given-names></name><article-title>GLORYx: Prediction of the Metabolites Resulting from
Phase 1 and Phase 2 Biotransformations of Xenobiotics</article-title>. <source>Chem. Res. Toxicol.</source><year>2021</year>, <volume>34</volume> (<issue>2</issue>), <fpage>286</fpage>–<lpage>299</lpage>. <pub-id pub-id-type="doi">10.1021/acs.chemrestox.0c00224</pub-id>.<pub-id pub-id-type="pmid">32786543</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref5">
      <mixed-citation publication-type="journal" id="cit5"><name><surname>Flynn</surname><given-names>N. R.</given-names></name>; <name><surname>Dang</surname><given-names>N. L.</given-names></name>; <name><surname>Ward</surname><given-names>M. D.</given-names></name>; <name><surname>Swamidass</surname><given-names>S. J.</given-names></name><article-title>XenoNet:
Inference and Likelihood of Intermediate Metabolite Formation</article-title>. <source>J. Chem. Inf. Model.</source><year>2020</year>, <volume>60</volume> (<issue>7</issue>), <fpage>3431</fpage>–<lpage>3449</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.0c00361</pub-id>.<pub-id pub-id-type="pmid">32525671</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref6">
      <mixed-citation publication-type="journal" id="cit6"><name><surname>Hughes</surname><given-names>T. B.</given-names></name>; <name><surname>Dang</surname><given-names>N. L.</given-names></name>; <name><surname>Kumar</surname><given-names>A.</given-names></name>; <name><surname>Flynn</surname><given-names>N. R.</given-names></name>; <name><surname>Swamidass</surname><given-names>S. J.</given-names></name><article-title>Metabolic
Forest: Predicting the Diverse Structures of Drug Metabolites</article-title>. <source>J. Chem. Inf. Model.</source><year>2020</year>, <volume>60</volume> (<issue>10</issue>), <fpage>4702</fpage>–<lpage>4716</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.0c00360</pub-id>.<pub-id pub-id-type="pmid">32881497</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref7">
      <mixed-citation publication-type="journal" id="cit7"><name><surname>Rudik</surname><given-names>A. V.</given-names></name>; <name><surname>Bezhentsev</surname><given-names>V. M.</given-names></name>; <name><surname>Dmitriev</surname><given-names>A. V.</given-names></name>; <name><surname>Druzhilovskiy</surname><given-names>D. S.</given-names></name>; <name><surname>Lagunin</surname><given-names>A. A.</given-names></name>; <name><surname>Filimonov</surname><given-names>D. A.</given-names></name>; <name><surname>Poroikov</surname><given-names>V. V.</given-names></name><article-title>MetaTox: Web Application
for Predicting Structure and Toxicity of Xenobiotics’ Metabolites</article-title>. <source>J. Chem. Inf. Model.</source><year>2017</year>, <volume>57</volume> (<issue>4</issue>), <fpage>638</fpage>–<lpage>642</lpage>. <pub-id pub-id-type="doi">10.1021/acs.jcim.6b00662</pub-id>.<pub-id pub-id-type="pmid">28345905</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref8">
      <mixed-citation publication-type="journal" id="cit8"><name><surname>Filimonov</surname><given-names>D.</given-names></name>; <name><surname>Druzhilovskiy</surname><given-names>D.</given-names></name>; <name><surname>Lagunin</surname><given-names>A.</given-names></name>; <name><surname>Gloriozova</surname><given-names>T.</given-names></name>; <name><surname>Rudik</surname><given-names>A.</given-names></name>; <name><surname>Dmitriev</surname><given-names>A.</given-names></name>; <name><surname>Pogodin</surname><given-names>P.</given-names></name>; <name><surname>Poroikov</surname><given-names>V.</given-names></name><article-title>Computer-aided
prediction of biological activity spectra for chemical compounds:
opportunities and limitation</article-title>. <source>Biomed. Chem.</source><year>2018</year>, <volume>1</volume> (<issue>1</issue>), <elocation-id>e00004</elocation-id><pub-id pub-id-type="doi">10.18097/BMCRM00004</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref9">
      <mixed-citation publication-type="journal" id="cit9"><name><surname>Lagunin</surname><given-names>A.</given-names></name>; <name><surname>Zakharov</surname><given-names>A.</given-names></name>; <name><surname>Filimonov</surname><given-names>D.</given-names></name>; <name><surname>Poroikov</surname><given-names>V.</given-names></name><article-title>QSAR Modelling of Rat
Acute Toxicity on the Basis of PASS Prediction</article-title>. <source>Mol. Inf.</source><year>2011</year>, <volume>30</volume> (<issue>2–3</issue>), <fpage>241</fpage>–<lpage>250</lpage>. <pub-id pub-id-type="doi">10.1002/minf.201000151</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref10">
      <mixed-citation publication-type="journal" id="cit10"><name><surname>Rudik</surname><given-names>A.</given-names></name>; <name><surname>Bezhentsev</surname><given-names>V.</given-names></name>; <name><surname>Dmitriev</surname><given-names>A.</given-names></name>; <name><surname>Lagunin</surname><given-names>A.</given-names></name>; <name><surname>Filimonov</surname><given-names>D.</given-names></name>; <name><surname>Poroikov</surname><given-names>V.</given-names></name><article-title>Metatox - Web application for generation of metabolic
pathways and toxicity estimation</article-title>. <source>J. Bioinf.
Comput. Biol.</source><year>2019</year>, <volume>17</volume> (<issue>01</issue>), <fpage>1940001</fpage><pub-id pub-id-type="doi">10.1142/S0219720019400018</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref11">
      <mixed-citation publication-type="journal" id="cit11"><name><surname>Filimonov</surname><given-names>D. A.</given-names></name>; <name><surname>Druzhilovskiy</surname><given-names>D. S.</given-names></name>; <name><surname>Lagunin</surname><given-names>A. A.</given-names></name>; <name><surname>Gloriozova</surname><given-names>T. A.</given-names></name>; <name><surname>Rudik</surname><given-names>A. V.</given-names></name>; <name><surname>Dmitriev</surname><given-names>A. V.</given-names></name>; <name><surname>Pogodin</surname><given-names>P.</given-names></name>; <name><surname>Poroikov</surname><given-names>V.</given-names></name><article-title>Computer-aided
prediction of biological activity spectra for chemical compounds:
opportunities and limitation</article-title>. <source>Biomed. Chem.</source><year>2018</year>, <volume>1</volume>, <elocation-id>e00004</elocation-id><pub-id pub-id-type="doi">10.18097/BMCRM00004</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref12">
      <mixed-citation publication-type="journal" id="cit12"><name><surname>Wishart</surname><given-names>D. S.</given-names></name>; <name><surname>Feunang</surname><given-names>Y. D.</given-names></name>; <name><surname>Guo</surname><given-names>A. C.</given-names></name>; <name><surname>Lo</surname><given-names>E. J.</given-names></name>; <name><surname>Marcu</surname><given-names>A.</given-names></name>; <name><surname>Grant</surname><given-names>J. R.</given-names></name>; <name><surname>Sajed</surname><given-names>T.</given-names></name>; <name><surname>Johnson</surname><given-names>D.</given-names></name>; <name><surname>Li</surname><given-names>C.</given-names></name>; <name><surname>Sayeeda</surname><given-names>Z.</given-names></name>; <name><surname>Assempour</surname><given-names>N.</given-names></name>; <name><surname>Iynkkaran</surname><given-names>I.</given-names></name>; <name><surname>Liu</surname><given-names>Y.</given-names></name>; <name><surname>Maciejewski</surname><given-names>A.</given-names></name>; <name><surname>Gale</surname><given-names>N.</given-names></name>; <name><surname>Wilson</surname><given-names>A.</given-names></name>; <name><surname>Chin</surname><given-names>L.</given-names></name>; <name><surname>Cummings</surname><given-names>R.</given-names></name>; <name><surname>Le</surname><given-names>D.</given-names></name>; <name><surname>Pon</surname><given-names>A.</given-names></name>; <name><surname>Knox</surname><given-names>C.</given-names></name>; et al. <article-title>DrugBank 5.0: a major update to the DrugBank database for 2018</article-title>. <source>Nucleic Acids Res.</source><year>2018</year>, <volume>46</volume> (<issue>D1</issue>), <fpage>D1074</fpage>–<lpage>D1082</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkx1037</pub-id>.<pub-id pub-id-type="pmid">29126136</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref13">
      <mixed-citation publication-type="journal" id="cit13"><name><surname>Djoumbou-Feunang</surname><given-names>Y.</given-names></name>; <name><surname>Fiamoncini</surname><given-names>J.</given-names></name>; <name><surname>Gil-de-la-Fuente</surname><given-names>A.</given-names></name>; <name><surname>Greiner</surname><given-names>R.</given-names></name>; <name><surname>Manach</surname><given-names>C.</given-names></name>; <name><surname>Wishart</surname><given-names>D. S.</given-names></name><article-title>BioTransformer: a comprehensive computational tool
for small molecule metabolism prediction and metabolite identification</article-title>. <source>J. Cheminf.</source><year>2019</year>, <volume>11</volume> (<issue>1</issue>), <fpage>2</fpage><pub-id pub-id-type="doi">10.1186/s13321-018-0324-5</pub-id>.</mixed-citation>
    </ref>
    <ref id="ref14">
      <mixed-citation publication-type="journal" id="cit14"><name><surname>Mendez</surname><given-names>D.</given-names></name>; <name><surname>Gaulton</surname><given-names>A.</given-names></name>; <name><surname>Bento</surname><given-names>A. P.</given-names></name>; <name><surname>Chambers</surname><given-names>J.</given-names></name>; <name><surname>De Veij</surname><given-names>M.</given-names></name>; <name><surname>Félix</surname><given-names>E.</given-names></name>; <name><surname>Magariños</surname><given-names>M.</given-names></name>; <name><surname>Mosquera</surname><given-names>J. F.</given-names></name>; <name><surname>Mutowo</surname><given-names>P.</given-names></name>; <name><surname>Nowotka</surname><given-names>M.</given-names></name>; <name><surname>Gordillo-Marañón</surname><given-names>M.</given-names></name>; <name><surname>Hunter</surname><given-names>F.</given-names></name>; <name><surname>Junco</surname><given-names>L.</given-names></name>; <name><surname>Mugumbate</surname><given-names>G.</given-names></name>; <name><surname>Rodriguez-Lopez</surname><given-names>M.</given-names></name>; <name><surname>Atkinson</surname><given-names>F.</given-names></name>; <name><surname>Bosc</surname><given-names>N.</given-names></name>; <name><surname>Radoux</surname><given-names>C. J.</given-names></name>; <name><surname>Segura-Cabrera</surname><given-names>A.</given-names></name>; <name><surname>Hersey</surname><given-names>A.</given-names></name>; <name><surname>Leach</surname><given-names>A. R.</given-names></name><article-title>ChEMBL:
towards
direct deposition of bioassay data</article-title>. <source>Nucleic
Acids Res.</source><year>2019</year>, <volume>47</volume> (<issue>D1</issue>), <fpage>D930</fpage>–<lpage>D940</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gky1075</pub-id>.<pub-id pub-id-type="pmid">30398643</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref15">
      <mixed-citation publication-type="journal" id="cit15"><name><surname>Filimonov</surname><given-names>D.</given-names></name>; <name><surname>Zakharov</surname><given-names>A.</given-names></name>; <name><surname>Lagunin</surname><given-names>A.</given-names></name>; <name><surname>Poroikov</surname><given-names>V.</given-names></name><article-title>QNA-based “Star
Track” QSAR approach</article-title>. <source>SAR QSAR Environ.
Res.</source><year>2009</year>, <volume>20</volume> (<issue>7–8</issue>), <fpage>679</fpage>–<lpage>709</lpage>. <pub-id pub-id-type="doi">10.1080/10629360903438370</pub-id>.<pub-id pub-id-type="pmid">20024804</pub-id>
</mixed-citation>
    </ref>
    <ref id="ref16">
      <mixed-citation publication-type="journal" id="cit16"><name><surname>Kawato</surname><given-names>Y.</given-names></name>; <name><surname>Aonuma</surname><given-names>M.</given-names></name>; <name><surname>Hirota</surname><given-names>Y.</given-names></name>; <name><surname>Kuga</surname><given-names>H.</given-names></name>; <name><surname>Sato</surname><given-names>K.</given-names></name><article-title>Intracellular
roles of SN-38, a metabolite of the camptothecin derivative CPT-11,
in the antitumor effect of CPT-11</article-title>. <source>Cancer Res.</source><year>1991</year>, <volume>51</volume> (<issue>16</issue>), <fpage>4187</fpage>–<lpage>4191</lpage>.<pub-id pub-id-type="pmid">1651156</pub-id>
</mixed-citation>
    </ref>
  </ref-list>
</back>
